Chapman University

Chapman University Digital Commons
Pharmaceutical Sciences (PhD) Dissertations

Dissertations and Theses

Winter 5-2021

Pathogenesis of Dry Eye in Graft Versus Host Disease (GVHD):
Role of Ocular Mucins and Conjunctival Fibrosis
Kiumars Shamloo
Chapman University, shaml103@mail.chapman.edu

Follow this and additional works at: https://digitalcommons.chapman.edu/
pharmaceutical_sciences_dissertations
Part of the Animal Experimentation and Research Commons, Eye Diseases Commons, and the
Pharmacology Commons

Recommended Citation
Shamloo, K. Pathogenesis of Dry Eye in Graft Versus Host Disease (GVHD): Role of Ocular Mucins and
Conjunctival Fibrosis. [dissertation]. Irvine, CA: Chapman University; 2021. https://doi.org/10.36837/
chapman.000230

This Dissertation is brought to you for free and open access by the Dissertations and Theses at Chapman
University Digital Commons. It has been accepted for inclusion in Pharmaceutical Sciences (PhD) Dissertations by
an authorized administrator of Chapman University Digital Commons. For more information, please contact
laughtin@chapman.edu.

PATHOGENESIS OF DRY EYE IN GRAFT VERSUS HOST DISEASE (GVHD): ROLE
OF OCULAR MUCINS AND CONJUNCTIVAL FIBROSIS
A Dissertation by
Kiumars Shamloo

Chapman University
Irvine, CA
School of Pharmacy
Submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Pharmaceutical Sciences
May 2021

Committee in charge:
Ajay Sharma, Ph.D. Chair
Keykavous Parang, Ph.D.
Surya M. Nauli, Ph.D.
Rennolds Ostrom, Ph.D.
Jennifer Totonchy, Ph.D.
Jason Yamaki, Pharm. D., Ph.D.

The disse rtation of Kiumars Shamloo is approved

Ajay Sharma, Ph.D. Chair

Keykavous Parang, Pharm.D., Ph.D.

Surya M. Nauli, Ph.D.

Rennolds Ostrom, Ph.D.

Jennifer Totonchy, Ph.D.

fo�mak1 (Mar 2, 202112:16 PST)

Jason Yamaki, Pharm.D., Ph.D.

January 2021

PATHOGENESIS OF DRY EYE IN GRAFT VERSUS HOST DISEASE (GVHD): ROLE
OF OCULAR MUCINS AND CONJUNCTIVAL FIBROSIS
Copyright © 2021
by Kiumars Shamloo

III

ACKNOWLEDGEMENT
This dissertation would not have been possible without the inspiration and support of
several wonderful individuals; my thanks and appreciation to all of them for being part of
this journey and making this thesis possible. I owe my deepest gratitude to my supervisor
Dr. Ajay Sharma for his instrumental role in shaping this project, his expertise, support,
feedback, and time. With his consistent guidance, I have been successful in conducting
this research and complete this dissertation. I am grateful to extend my thanks to other
students Priya Mistry, Jacob Baker, Judy Weng, and laboratory technicians: Ashley
Barbarino and Christopher Ross, for helping me around the projects. My sincere thanks
also to my committee members: Dr. Surya Nauli, Dr. Keykavous Parang, Dr. Rennolds
Ostrom, Dr. Jennifer Totonchi, Dr. Jason Yamaki, for their insightful comments and
encouragement. Finally, my sincere gratitude to my family for their continuous and
unparalleled love, help, and support. I am grateful to my wife for always being there for
me as a friend. I am forever indebted to my sons Danny and Sam for their understanding
and encouragement to finish this program. I appreciate their patience for all those years
that I missed and didn’t spend enough time with them. Special thanks to all people who,
along the way, believed in me

IV

LIST OF PUBLICATIONS:

1. Alfuraih S, Barbarino A, Ross C, Shamloo K, Jhanji V, Zhang M, Sharma A. Effect of
High Glucose on Ocular Surface Epithelial Cell Barrier and Tight Junction Proteins.
Invest Ophthalmol Vis Sci. 2020; 61, 3.
2. Mohieldin AM, Rajasekharreddy P, Sherpa RT, Alanazi M, Ashwaq, Alanazi A,
Shamloo K, Ahsan A, AbouAlaiwi WA, Moresco JJ, Yates JR, Naul SM. Proteomic
Identification Reveals the Role of Ciliary Extracellular-Like Vesicle in Cardiovascular
Function. Adv. Sci. 2020; 1903140
3. Shamloo K, Barbarino A, Alfuraih S, Sharma A. Graft Versus Host DiseaseAssociated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a
Mucin Secretagogue. Invest Ophthalmol Vis Sci. 2019; 60: 4511-19
4. Park SE, Shamloo K, Kristedja TA, Darwish S, Bisoffi M, Parang K, Tiwari RK. EDBFN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer. Int J Mol Sci.
2019; 20. pii: E3291.
5. Pala R, Mohieldin AM, Sherpa RT, Kathem SH, Shamloo K, Luan Z, Zhou J, Zheng
JG, Ahsan A, Nauli SM. Ciliotherapy: Remote Control of Primary Cilia Movement and
Function by Magnetic Nanoparticles. ACS Nano. 2019; 13:3555-72
6. Pala R, Mohieldin AM, Shamloo K, Sherpa RT, Kathem SH, Zhou J, Luan Z, Zheng
JG, Ahsan A, Nauli SM. Personalized Nanotherapy by Specifically Targeting Cell
Organelles to Improve Vascular Hypertension. Nano Lett. 2019;19: 904-14
7. Amirrad F, Bousoik E, Shamloo K, Al-Shiyab H, Nguyen VV, Montazeri Aliabadi H.
Alzheimer's Disease: Dawn of a New Era? J Pharm Pharm Sci. 2017; 20: 184-225.

V

8. Shamloo K, Chen J, Sardar J, Sherpa RT, Pala R, Atkinson KF, Pearce WJ, Zhang
L, Nauli SM. Chronic Hypobaric Hypoxia Modulates Primary Cilia Differently in Adult
and Fetal Ovine Kidneys. Front Physiol. 2017; 8: 677

VI

LIST OF CONFERENCE PRESENTATIONS:
1. Shamloo K, Barbarino A, Alfuraih S, Sharma A. Role of mucins in the pathogenesis
of dry eye associated with graft versus host disease (GVHD). Poster presented at
Annual Meeting of Association for Research in Vision and Ophthalmology, Vancouver,
British Columbia, Canada April 27-May 2 2019.
2. Shamloo K, Alfuraih S, Barbarino A, Ross C, Sharma A. Effect of high glucose on the
tight junction proteins of corneal and conjunctival epithelial cells. Poster accepted for
presentation at 2020 annual meeting of Association for Research in Vision and
ophthalmology at Baltimore, but the meeting was cancelled due to COVID-19
3. Mistry P, Shamloo K, Ross C, Sharma A. Comparative analysis of hyperosmotic
stress-mediated modulation of cytokine gene expression in human conjunctival and
corneal epithelial cells. Poster accepted for presentation at 2020 annual meeting of
Association for Research in Vision and ophthalmology at Baltimore, but the meeting
was cancelled due to COVID-19

VII

ABSTRACT
PATHOGENESIS OF DRY EYE IN GRAFT VERSUS HOST DISEASE (GVHD): ROLE
OF OCULAR MUCINS AND CONJUNCTIVAL FIBROSIS
by Kiumars Shamloo
Allogenic hematopoietic stem cell transplantation is a procedure that offers a possible
cure for hematologic cancers and other hematologic disorders. Unfortunately, despite the
increasing survival rate of patients, the quality of their life is adversely affected by the
allogeneic bone marrow transplantation’s major side effect i.e Graft vs. Host Disease
(GVHD). GVHD is a complex, multi-organ disease resulting from an immunological attack
by donor engrafted immune cells to host organs, including the eye surface. Mostly based
on the time of disease onset after transplantation, GVHD is divided into the acute and
chronic phase. The eyes may be involved in both acute and chronic GVHD, although
ocular involvement is more common in the chronic GVHD with a more severe
presentation. As high as 40%-60% of patients with chronic GVHD suffer from debilitating
ocular surface damage manifesting as severe dry eye and cicatricial conjunctivitis.
Several pathological mechanisms likely contribute to the etiology of ocular GVHDassociated dry eye disease. Despite the high frequency of ocular surface involvement in
patients experiencing GVHD, little is known about the underlying pathogenesis
responsible for ocular GVHD-associated dry eye. In our first manuscript, using a mouse
model of allogeneic transplantation, we demonstrated that ocular GVHD causes a
decrease in tear film volume and corneal keratopathy. These ocular surfaces changes
are accompanied by a significant decrease in the area and thickness of corneal
glycocalyx, a decrease in ocular surface mucins, MUC4 and MUC5AC and loss of
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conjunctival goblet cells. Our data showed that topical treatment by mucin secretagogue,
rebamipide, partially attenuates GVHD-associated damage to ocular surface.
Hyperosmolar tears are a consistent feature of dry eye disease. Our data demonstrated
that hyperosmolar stress increases the gene expression of NFAT5, a tonicity-related
transcription factor and pro-inflammatory cytokines (IL1, IL6, TNFα, IFN-γ) in human
corneal and conjunctival epithelial cells. Next, we demonstrated that these
proinflammatory cytokines differentially modulate the expression of MUC 1, and MUC 4
in ocular surface epithelial cells, but they do not cause any notable change in glycocalyx
or apoptotic cell death in stratified human corneal and conjunctival epithelial cells.
Immune-mediated ocular surface damage in GVHD can initiate a wound healing response
leading to fibrosis in the conjunctiva, a fibroblast-rich tissue. Conjunctival fibrosis may
underlie the noted decrease in goblet cells and ocular surface mucins, thus contributing
to GVHD-associated dry eye. Our results demonstrated that ocular GVHD causes a
significant increase in expression of α-smooth muscle actin (SMA), a marker of
myofibroblasts, in the conjunctiva. Immunostaining detected the presence of large
number of myofibroblasts in bulbar orbital conjunctiva of GVHD mice. An increase in the
components of renin-angiotensin system component (RAS), angiotensinogen and
angiotensin converting enzyme, was also noted in the conjunctiva suggesting that ocular
GVHD causes conjunctival fibrosis by myofibroblast formation and activation of
conjunctival RAS.
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CHAPTER 1
Introduction
Over the past few decades, allogeneic hematopoietic stem cell transplantation has
emerged as a potentially curative therapy for some hematologic malignancies and
hemoglobinopathies1. Despite the advances in HLA matching and the use of
immunosuppressive drugs, graft versus host disease (GVHD) remains a frequent
complication of allogeneic hematopoietic stem cell transplantation. GVHD is an immune
condition caused by a complex interplay between donor immune cells, host immune
organs, and host tissues 2-6. Depending upon the time of onset and clinical manifestations,
GVHD is divided into the acute and chronic phases. Acute GVHD primarily affects the
liver, skin, and intestine. On the other hand, chronic GVHD causes a high incidence of
ocular complications 7-9.
Ocular GVHD
Ocular GVHD most often presents as severe dry eye and ocular surface disease,
which can have a profound impact on the quality of life in its survivors 6. It is diagnosed
based on eye-related signs and symptoms such as hyperemia, hemorrhagic
conjunctivitis, pseudomembrane formation, lagophthalmos, pain, blurry vision, foreign
body sensation, burning sensation, serious light sensitivity, acute conjunctivitis and
corneal ulceration10.It happens in more than 60% of patients with chronic GVHD10.
Without adequate treatment, dry eye disease in patients with GVHD may advance to
corneal keratopathy, ulceration and lead to impairment of vision11.

1

Ocular surface mucins and glycocalyx
Tear film is a thin layer of fluid that covers the eye surface. Normal tear film is critical for
keeping the ocular surface hydrated and lubricated, thus preventing desiccation-induced
damage to the ocular surface12. The lacrimal functional unit, including eye surface nerves,
ocular surface glycocalyx, lacrimal glands, meibomian glands, and normal blinking
response, all contribute collectively to a healthy tear film's secretion and maintenance12.
The tear film, primarily made up of a muco-aqueous gel layer that underlies and partially
mixes with an overlaying lipid layer, is critical for keeping the eye surface hydrated and
lubricated 12. Tear film's mucous layer mainly consists of membrane-bound and secreted
mucins. Mucins are high molecular weight glycoproteins made up of a protein core with
extensive glycan N-acetyl galactosamine side chains13. Heavy glycosylation imparts a
negative charge and hydrophilicity to the mucins14. These structural features account for
their two vital physiological functions of repelling pathogens and keeping the eye surface
hydrated and lubricated. The tear film mucins include the membrane-bound mucins
(MUC): MUC1, MUC4, MUC16, soluble MUC7; it also includes the gel-forming secreted
mucins MUC19, MUC5AC15. The membrane-bound mucins which are expressed on the
apical surface of corneal and conjunctival epithelial cells, are glycosylated and sialylated
along with galectin 3 form a continuous layer called glycocalyx. which help to protect cells
against mechanical and chemical damage, prevent pathogen penetration into the eye,
reduce friction during blinking, and maintain the hydrophilicity of the ocular surface.
MUC5AC is mainly secreted by the goblet cells16. How GVHD affects ocular surface
mucins and glycocalyx is not known 15.

2

Besides providing hydration, lubrication and antimicrobial functions, ocular surface
membrane-tethered mucins have also been shown to act as signaling molecules. Specific
localization of mucins to the apical surfaces of epithelial cells suggests that their signaling
functions may be important as sensor mechanisms in response to invasion or damage of
epithelia. MUC1 and MUC4 are the two membrane mucins, which have apparently similar
structures. Recent studies have also implicated them in cellular signaling. MUC4 has
been shown to act as an intramembrane receptor-ligand for the receptor tyrosine kinase
ErbB2/HER2/Neu triggering specific phosphorylation of the ErbB2 in the absence of other
ErbB ligands17. MUC1, through its highly conserved cytoplasmic tail, has been shown to
bind to β-catenin17.

Hyperosmolar stress and ocular surface epithelial cells
Osmotic stress is one of the common stresses for organs, such as the kidney, skin,
respiratory track, and eye. Osmotic stress can have longstanding detrimental effects that
can cause tissue damage in these organs. Increased levels of tear osmolarity is a
consistent feature of GVHD dry eye18. Nuclear factor of activated T-cells (NFAT) proteins
is a family of transcription factors, which were originally identified to be expressed in most
immune-system cells. This family contains five members: NFAT1 (NFATp), NFAT2
(NFATc), NFAT3, 4, (NFATx), and NFAT5 (tonicity response element-binding protein or
EBP27) was initially identified as a transcription factor involved in cellular responses to
hypertonic stress28. NFAT5 is activated by phosphorylation under a hyperosmotic
environment and is amongst the few known tonicity-regulated transcription factors in
mammalian cells. NFAT5 transcriptionally regulates the expression of target genes

3

responsible for the metabolism of organic osmolytes, including aldose reductase, taurine
transporter, betaine/GABA transporter, and sodium/myo-inositol transporter. NFAT5 also
induces molecular chaperones, such as heat shock protein 70 and 9419-23. Does osmotic
stress modulate NFAT5 expression in corneal and conjunctival epithelial cells is worth
testing?
Patients with dry eye have been shown to have elevated levels of proinflammatory
cytokines. How tear hyperosmolarity affects the production of proinflammatory cytokines
from ocular surface epithelial cells needs to be investigated. Proinflammatory cytokines
released by immune cells in GVHD have been shown to exert a damaging effect on
various tissues

17,19

. The promoter region of genes encoding for mucins has response

elements for signaling pathways activated by these proinflammatory cytokines,
suggesting that these cytokines can modulate the gene expression of mucins

24,25

.

Additionally, these cytokines have been shown to induce the expression of enzymes,
such as heparanase and hyaluronidase that may have a detrimental effect on the
glycocalyx26.
GVHD associated fibrosis
GVHD patients suffer from longstanding fibrosis of skin, liver, lungs and
gastrointestinal tract resulting in clinical manifestations of the disease such as
scleroderma, bronchiolitis obliterans syndrome, and liver damage. Mouse models of
chronic GVHD manifest fibrosis of skin, liver, lungs, and gastrointestinal tract27,28. There
are anecdotal clinical reports of conjunctival fibrosis in GVHD patients29,30. However,
there is no systemic preclinical study in a mouse model that examines the time course
and severity of conjunctival fibrosis and its correlation to GVHD associated dry eye.

4

Myofibroblasts are key feature of fibrosis and can form by trans-differentiation of
resident fibroblasts, mesenchymal cells, and circulating fibrocytes31-33. Myofibroblasts are
contractile metabolically active cells that synthesis large quantities of extracellular matrix
proteins and play a key role in fibrosis31-33. Conjunctiva has resident fibroblasts and donororigin fibrocytes have also been demonstrated in the eyes of GVHD patients34. Thus,
conjunctival fibrosis may be likely caused myofibroblast formation and excessive
deposition of extracellular matrix.
Conjunctival tissue has been shown to express components of local renin
angiotensin system (RAS), including renin, angiotensinogen, angiotensin converting
enzyme (ACE) and AT1 receptors35-39. Conjunctival injury such as trabeculectomy has
been shown to upregulate RAS40. Angiotensin II has been shown to cause
transdifferentiation of conjunctival fibroblasts to myofibroblasts

41

. Profibrotic cytokines

such as transforming growth factor beta (TGF-β), PDGF, CTGF released by immune cells
in GVHD can serve as the initial trigger for fibroblasts transdifferentiation to
myofibroblasts42,43. An interaction between RAS and profibrotic cytokines, especially
TGF-β and RAS, can serve to amplify and perpetuate conjunctival fibrosis.
Hypothesis
GVHD-associated dry eye is caused by ocular surface glycocalyx damage, mucin
layer dysfunction, and conjunctival fibrosis. We tested this hypothesis using the following
aims:
Specific Aim1: To examine the role of glycocalyx and mucins in the etiology of GVHDassociated dry eye. To test this aim

5

1a: we studied the effect of GVHD on ocular surface glycocalyx, ocular surface
membrane-bound mucins, secreted tear film mucins, and conjunctival goblet cells;
1b: we investigated the effect of augmentation of ocular surface mucins as a
pharmacological approach to treat GVHD-associated dry eye.
Specific Aim 2: To examine the effect of hyperosmolar stress on the release of proinflammatory cytokines. To test this aim
2a: we studied the effect of hyperosmolar stress on the release of proinflammatory
cytokines from ocular surface epithelial cells.
2b: we investigated the effect of proinflammatory cytokines on ocular surface glycocalyx
and mucins
Specific Aim 3: To examine the role of conjunctival fibrosis in etiology of GVHDassociated dry eye. To test this aim,
3a: we studied whether GVHD causes conjunctival fibrosis and myofibroblast formation.
3b: we investigated the role of local ocular renin angiotensin system (RAS) in GVHDmediated conjunctival fibrosis.

Figure 1. Central Hypothesis
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Figure 2. Structure of the four types of ocular surface epithelial cells
mucins (MUC)
A) secreted, gel forming MUC5AC which produce by gablet cells.
B) membrane bond mucins MUC1, MUC4, MUC 16 expressed by the ocular
surface epithelia.45

Figure 3. Ocular surface barrier consisting of glycocalyx and intracellular junctions42.
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Abstract
Purpose: The present study was designed to investigate the role of ocular surface
mucins in GVHD-associated dry eye. The ameliorative effect of topical rebamipide, a
mucin secretagogue, on GVHD-associated dry eye was also tested.
Methods: A mouse model of allogeneic transplantation was used to induce ocular
GVHD with C57BL/6 as donors and B6D2F1 as recipient mice. Phenol red thread
method and fluorescein staining were used to quantify tear secretion and corneal
keratopathy. At 8 weeks after the allogeneic transplantation, corneas were harvested to
perform glycocalyx staining and confocal microscopy. The goblet cell staining was
performed using periodic acid Schiff’s staining. Corneal and tear film levels of Mucin1,
4, 16, 19 and 5AC were quantified using ELISA and real-time PCR. Rebamipide was
applied topically twice daily to mice eyes and BSS was used as vehicle control.
Results: Allogeneic transplantation resulted in ocular GVHD-associated dry eye
characterized by a significant decrease in tear film volume and the onset of corneal
keratopathy. Ocular GVHD caused a significant decrease in the area and thickness of
corneal glycocalyx. A significant decrease in the goblet cells was also noted. A
significant decrease in mucin 4 and mucin 5AC levels was also observed. Topical
treatment with rebamipide partially attenuated ocular GVHD-mediated decrease in tear
film volume and significantly reduced the severity of corneal keratopathy.
Conclusions: Ocular GVHD has a detrimental impact on ocular surface glycocalyx and
mucins. Rebamipide, a mucin secretagogue, partially prevents ocular GVHD-associated
decrease in the tear film and reduces the severity of corneal keratopathy.
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Introduction:
Allogeneic hematopoietic stem cell transplantation is a successful treatment option for
hematological malignancies. However, graft versus host disease (GVHD) is a serious
complication of hematopoietic stem cell transplantation, and its incidence remains high
in spite of the advances in HLA matching. Depending upon the time of onset and clinical
manifestations, GVHD is divided into the acute and chronic phase. Acute GVHD
primarily affects the liver, skin, and intestine1-3. On the other hand, chronic GVHD has
been shown to cause a high incidence of ocular complications4,5. As high as 60-90% of
chronic GVHD patients suffer from ocular manifestations4,5. Ocular signs in chronic
GVHD patients may be noticeable even before the other systemic symptoms6-8. Dry eye
disease is one of the most frequent complications of ocular GVHD9,10. The dry eye
disease in ocular GVHD patients is severe, resulting in signs of blurred vision,
photophobia, redness, gritty sensation, and pain9,10. These symptoms cause significant
visual discomfort and reduce the overall quality of life of GVHD patients9,10. In the
absence of timely and appropriate treatment, dry eye disease in GVHD patients may
progress to corneal keratopathy, ulceration, and visual impairment.
Lacrimal functional unit including ocular surface nerves, apical surface
glycocalyx, lacrimal glands, meibomian glands and a normal blinking response all
collectively contribute to the secretion and maintenance of a healthy tear film. Tear film
is critical for keeping the ocular surface hydrated and lubricated, thus preventing
desiccation-induced damage to the ocular surface. Tear film is comprised of mucous,
aqueous and lipid layers. Mucous layer of tear film is primarily comprised of membranebound and secreted mucins11-15. Mucins are high molecular weight glycoproteins made
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up of a protein core with extensive glycan N-acetyl galactosamine side chains. The
heavy glycosylation imparts the mucins with hydrophilicity and a high negative charge1115

.
These structural features account for their two key physiological functions of

repelling pathogens and keeping the ocular surface hydrated11-15. The mucous layer of
tear film contains membrane-bound mucins (MUC): MUC1, MUC4, MUC16, soluble
MUC7 and, gel-forming secreted mucins, MUC19, MUC5AC and MUC5B11-15. The
membrane-bound mucins are expressed on the apical surface of corneal and
conjunctival epithelial cells. The gel-forming mucins MUC5AC and MUC5B are primarily
secreted by the goblet cells present in the conjunctiva and lacrimal gland respectively.
Lacrimal gland also releases soluble MUC7 in the tear film. Tear film mucins retard tear
film evaporation keep the eye surface lubricated and entrap allergens and pathogens1115

.
Patients with dry eye disease show reduced levels of mucins or an alteration in

the degree of their glycosylation16-18. A significant aqueous deficit has been observed in
the tears of GVHD patients suffering from dry eye19. Multiple studies have shown that
GVHD causes lacrimal gland fibrosis 20-23. How GVHD impacts ocular surface mucins is
not known. Therefore, the aim of the present study was to investigate the role of ocular
surface mucins in GVHD-associated dry eye and to test the ameliorative effect of
rebamipide, a mucin secretagogue, on GVHD-associated dry eye.
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Methods:
Allogenic bone marrow transplantation
The animal protocol was approved by Institutional Animal Care and Use
Committee of Chapman University. All the animal experiments were conducted in
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research. A previously published mouse model of MHC class I mismatch induced
ocular GVHD was used23. The B6D2F1 mice (The Jackson Laboratories, Bar Harbor,
ME, USA) having a heterozygous MHC haplotype b/d were used as recipients and
C57BL/6 mice (The Jackson Laboratories, Bar Harbor, ME, USA) having a homozygous
haplotype b/b were used as donors. The bone marrow and spleen cells were harvested
from 8 weeks old donor female C57B6 mice. Ten weeks old female B6D2F1 recipient
mice were exposed to a total body irradiation of 1100 cGy delivered in two equally
divided doses three hours apart (RS 2000 X-ray Biological Irradiator, Rad Source
Technologies, Buford, GA, USA). The irradiated B6D2F1 mice were then injected with
2X106 spleen cells and 5X106 bone marrow cells obtained from C57B6 mice by retroorbital injection. The mice were housed in a sterile cage, fed with diet gel (ClearH2O,
Portland, ME, USA) and received sulfatrim (0.672 mg/ml) in their drinking water for the
first 14 days. At 8 weeks after the transplantation, animals were euthanized by CO2
administration for the collection of ocular tissue.
The study design included three different group of mice. 1) Control group (No
transplant) n= 6 mice included age matched B6D2F1 mice, which did not receive any
bone marrow or spleen cell transplantation. 2) Ocular GVHD group n= 12 included
B6D2F1 mice that received allogenic bone marrow and spleen cell transplantation.
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3) Rebamipide treated group n=6 included B6D2F1 mice that received allogenic bone
marrow and spleen cell transplantation and were treated with 2 μl topical ophthalmic
drops of 2% rebamipide suspended in BSS in left eye two times daily. The right eye of
these mice received 2 μl topical ophthalmic drops of vehicle BSS two times daily.
Tear quantification:
Tear secretion was quantified by phenol red thread test before the allogeneic
transplantation and at weekly intervals after the transplantation. The phenol red
impregnated thread (FCI Ophthalmics, Pembroke, MA, USA) was placed in the lower
eyelid of mice on the temporal side for 1 minute. Upon wetting by tears, the phenol red
thread changes color from yellow to red due to pH change. After 1 minute, the thread
was removed, and the length of the red color on the thread was measured. The length
was converted to the volume by using a standard curve plotted by measuring the length
of the phenol red thread wetted with a known volume of artificial tears.
Fluorescein staining:
Mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and
xylazine (10 mg/kg). A 2 μl sterile solution of 0.5% fluorescein was applied to mouse
eye, and imaging was performed under a green fluorescent filter using
stereomicroscope equipped with a digital camera. The captured corneal images were
divided into hypothetical four quadrants for scoring the keratopathy using a previously
published method24. Each quadrant was scored as follows: No staining= 0; slightly
punctate
staining less than 30 spots= 1; punctate staining more than 30 spots, but not diffuse= 2;
diffuse staining but no positive plaque= 3; positive fluorescein plaque= 4. The scores of
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each quadrant was added to arrive at a final grade (total maximum possible score=16).
Glycocalyx staining:
The eyes were collected from euthanized animals at 8 weeks after the allogeneic
transplantation and were fixed by immersing overnight in 4% paraformaldehyde. The
corneas were isolated and blocked in 5% BSA for 20 minutes. Glycocalyx staining on
the corneas was performed using 1.5 μg/ml solution of Alexa 488 conjugated wheat
germ agglutinin lectin (Thermo Fisher Scientific, Hanover Park, IL, USA) for 20 minutes.
Wheat germ agglutinin lectin binds to the N-acetylglucosamine and N-acetylneuraminic
acid residues present on the ocular surface glycocalyx and have been used in multiple
studies, including human patients, to stain corneal glycocalyx25-27. The stained corneas
were imaged using a confocal microscope. A total of 4 images were captured from each
cornea. The quantification of glycocalyx stained area and thickness was performed
using Image J software in a blinded manner.
Goblet Cell Staining:
The eyes along with eyelids were harvested from euthanized animals at 8 weeks
after the allogeneic transplantation and processed for paraffin embedding. The 7 μm
thin paraffin sections were cut, and periodic Acid Schiff's (PAS) staining was performed
for goblet cells using a commercially available kit (Polysciences, Inc., Warrington, PA,
USA). The stained sections were imaged at 100X magnification using a brightfield
microscope (Keyence corporation of America, Itasca, IL, USA).
ELISA quantification of mucin 1, 4 & 16:
At 8 weeks after the allogeneic transplantation, animals were euthanized by CO2
administration. The eyeballs were collected, and the corneas were separated. The
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corneas were homogenized in RIPA buffer containing protease inhibitor (Pierce,
Thermo Fisher Scientific, Hanover Park, IL, USA). The total protein in the corneal
homogenates was quantified by BCA method using a commercially available kit (Pierce,
Thermo Fisher Scientific, Hanover Park, IL, USA). The Muc1, Muc4 and Muc16 levels
were quantified in the corneal protein lysates using commercially available ELISA kits
(LSBio, Seattle, WA, USA). The mucin levels were normalized for the milligram of total
protein in the corneal lysates.
ELISA quantification of mucin 5AC:
The Muc5ac levels were quantified in the tears collected from mice at 8 weeks
after the allogeneic transplantation. For tear collection, mice were lightly anesthetized
with isoflurane. A 1 μL solution of 1X PBS containing 0.1% BSA was placed on each
eye of the mouse and then collected back by using a Drummond microcapillary tube.
The 1 μL collected from each eye was pooled and added to 8 μL of BSS solution. The
tears were stored at -80°C for quantification of Muc5ac using a commercially available
ELISA kit (LSBio, Seattle, WA, USA).
Gene expression quantification of Mucin 1, 4, 16 & 19:
Corneas were harvested from animals at 8 weeks after transplantation as described
above. The mRNA was extracted from the corneas using the RNeasy Mini kit (RNeasy
kit; Qiagen Inc., Valencia, CA, USA). The mRNA was immediately reverse transcribed
to cDNA using a commercially available kit (Superscript III First-strand synthesis,
Thermo Fisher Scientific, Hanover Park, IL, USA) for cDNA synthesis. The cDNA was
used to quantify Muc1, Muc4, Muc16, and Muc19 gene expressions using real-time
PCR. A 20 μl reaction mixture containing 2 μl of cDNA, 2 μl of forward primer (200 nM),
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2 μl of reverse primer (200 nM), and 10 μl of 2X SYBR green supermix was run at a
universal cycle (95°C for 10 min, 40 cycles at 95°C for 15 s, and 55°C for 60 s) in a
thermocycler (Biorad CFX thermocycler, Bio-Rad Laboratories). β-actin was used as the
housekeeping gene. The relative change in gene expression was calculated using ΔΔCt
method.
Statistical Analysis:
The data is presented as mean + S.E.M. One-way ANOVA followed by Dunnet’s
and Duncan’s test was used to analyze time dependent changes in tear film volume for
Figure 1 and corneal keratopathy score for Figure 7B, respectively. The data presented
in Figures 2-6 for comparing control and allogeneic transplantation groups was
analyzed using unpaired t test. Two-way ANOVA was used for data analysis of tear film
volume presented in Figure 7 A.
Results:
Effect of ocular GVHD on tear film volume and corneal keratopathy:
The present study used MHC mismatched allogeneic transplantation mouse model that
has been shown to develop ocular GVHD23. Our results further confirm that this mouse
model of allogeneic transplant results in significant manifestations of dry eye due to
ocular GVHD as is evident from a decrease in tear film volume and appearance of
corneal keratopathy. Fig. 1 shows a baseline mean tear film volume of 300 nanoliters in
the mice prior to the allogeneic transplantation. After the bone marrow and spleen cell
transplantation, a statistically significant 3-fold decrease in tear film volume was noted
starting at 3 weeks, and this decrease persisted till the tested time point of 8 weeks. The
observed 2 weeks delay in the onset of tear film decrease is anticipated because
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immune-mediated damage to the lacrimal functional unit is expected to precede prior to
a decrease in tear film volume becomes apparent.
Fig. 2 shows a representative fluorescein-stained image of a mouse cornea
before (Fig. 2A) and at 8 weeks after the allogeneic bone marrow and spleen cell
transplantation (Fig. 2B). As can be seen in fig. 2B, the corneas of mice that underwent
allogeneic transplant showed significant punctate and plaque staining. The scoring of
fluorescein-stained corneal images was performed in a blinded manner using a
previously described method24. The corneas of mice that received allogeneic
transplantation had a mean fluorescein staining score of 8 (Fig. 2C), suggesting that
ocular GVHD caused a moderate to severe degree of corneal keratopathy.
Effect of ocular GVHD on corneal glycocalyx and goblet cells:
Corneal epithelial cells express 3 different types of membrane-tethered mucins
on their apical surface. These mucins together with galectin 3 form a continuous
network of glycocalyx. Wheat germ agglutinin lectin binds to the sialic acid residues
present on these mucins and has been previously used to stain the corneal
glycocalyx27. Fig. 3 shows the top and orthogonal projection confocal images of the
mouse corneas stained for glycocalyx using Alexa 488 conjugated wheat germ
agglutinin. The top view of confocal z stack images show a dense and uniformly
distributed glycocalyx staining in the corneas of control mice that did not receive any
transplantation (Fig. 3A). On the other hand, corneal glycocalyx was sparse and patchy
in the corneas obtained from mice at 8 weeks after they received allogeneic bone
marrow and spleen cell transplantation (Figure 3B). The glycocalyx-stained area was
quantified as percentage of the total corneal area using binary image analysis of 16
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images each of corneas obtained control mice and the mice that received allogeneic
transplantation (4 images captured from different parts of each cornea and n=4 mice).
As is evident from binary quantification data presented in Fig. 3C, a significant decrease
of 37% in glycocalyx stained area was observed in the mice corneas that received
allogeneic transplantation compared to the control mice without any transplantation. Fig.
3D and 3E show the orthogonal projection confocal Z stack images of glycocalyxstained corneas. A significant decrease in the glycocalyx thickness was observed in the
corneas obtained from mice that received allogeneic transplantation (Fig. 3D) compared
to control corneas obtained from mice without any transplantation (Fig. 3E). Glycocalyx
thickness was also quantified in16 images each obtained from corneas of control mice
(n=4) and from the corneas of mice that received allogeneic transplantation (n=4). Fig. 3
F shows a mean decrease of 33% in the corneal glycocalyx thickness in the mice that
received allogeneic transplantation compared to control mice.
Fig. 4 shows a representative image of periodic acid Schiff’s-stained goblet cells
in the eyelids of control mice and mice that underwent allogenic bone marrow and
spleen cell transplant. It is apparent from the staining that allogenic bone marrow and
spleen cell transplantation mediated ocular GVHD caused a notable decrease in the
number of goblet cells. It can also be noted that the morphology and mucin content of
goblet cells has also been altered by the ocular GVHD in mice that received allogenic
bone marrow and spleen cell transplant as compared to the control mice that did not
receive any transplantation.
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Effect of ocular GVHD on mucins:
We further investigated the effect of allogeneic bone marrow and spleen cell
transplantation associated with ocular GVHD on membrane bound Muc1, 4 and 16
mucins using corneal homogenates and on secreted Muc5ac in tear film. A slight
reduction inMuc1 (Fig. 5A) levels was noted in the corneal homogenates obtained from
mice at 8weeks after allogeneic bone marrow and spleen cell transplantation as
compared to the levels in the control corneal homogenates obtained from mice that did
not receive any transplantation. A statistically significant decrease in corneal
homogenate levels of Muc4 (Fig. 5B) and tear film levels of Muc5ac (Fig. 5D) was also
observed in the mice that underwent allogeneic transplant as compared to the control
mice. On the other hand, a slight increase in Muc16 was observed (Fig. 5C) in the
corneal homogenates of transplanted mice compared to control mice.
To test the effect of ocular GVHD on mucin gene expression, mRNA levels were
quantified in the corneas of control mice and in the cornea obtained from mice at 8
weeks after the allogeneic transplant. A significant increase in Muc1 gene expression
was observed in the corneas obtained from mice that received allogeneic
transplantation compared to control mice that did not receive any transplantation (Fig. 6
A). However, no significant change was noted in the mRNA levels of Muc4 (Fig. 6B),
Muc16 (Fig. 6C) and Muc19 (Fig. 6D) between the control mice without the
transplantation and mice that received allogeneic bone marrow and spleen cell
transplantation.
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Effect of topical rebamipide on ocular GVHD-mediated changes in tear film and
corneal keratopathy:
Lastly, we tested the effect of rebamipide, a mucin secretagogue, on ocular GVHD
mediated decrease in tear film volume and cornel keratopathy. As can be seen from the
Fig. 7 A, twice daily topical ophthalmic application of rebamipide attenuated ocular
GVHD-mediated decrease in tear film volume. The results were statistically significant
at week 3 and 4 compared to the GVHD mice who received allogeneic transplantation
but did not receive any eye drops. The BSS was used as a vehicle for compounding
rebamipide. Therefore, we also tested the effect of topical ophthalmic application of
BSS as vehicle, but BSS application in GVHD mice had no notable effect on the tear
film volume compared to untreated (no eye drops) control GVHD mice. Further,
rebamipideapplication also significantly mitigated ocular GVHD-mediated corneal
keratopathy (Fig. 7B). Rebamipide treated GVHD mice showed a mean corneal
keratopathy score of 3compared to a score of 8 for the untreated (no eye drops) GVHD
mice (Fig. 7B). It is interesting to note though that keeping the ocular surface hydrated
by BSS vehicle application also partly attenuated corneal keratopathy. BSS treated
GVHD mice showed
a mean corneal keratopathy score of 5 compared to a score of 8 for the untreated (no
eye drops) GVHD mice (Fig. 7B).
Discussion:
The apical surface of the corneal and conjunctival epithelium is covered with glycocalyx,
a thin layer of glycoproteins largely composed of membrane-tethered mucins and
galectin-328-30. The glycocalyx forms a boundary between the ocular surface epithelium

26

and the tear film. Glycocalyx serves to protect the cells against mechanical and
chemical damage. An intact glycocalyx is also essential to reduce the friction during
blinking and to keep the ocular surface hydrated28-30. We used fluorescent wheat germ
agglutinin labeling and whole cornea mount 3D confocal microscopy to visualize
glycocalyx on the corneas of GVHD mice. Wheat germ agglutinin binds to N-acetylglucosamines and sialic acid side chains of the membrane-tethered mucins and has
been used to specifically label, visualize and quantify glycocalyx in the cornea and
vascular endothelium25-27. Our data demonstrate a significant decrease in the area and
thickness of ocular surface glycocalyx in mice that received allogeneic bone marrow
and spleen cell transplantation suggesting that GVHD has a detrimental effect on the
ocular surface glycocalyx.
Membrane-tethered mucins are an integral component of glycocalyx. Thus, we
further examined the effect of GVHD on corneal epithelial membrane-tethered mucins.
Our results demonstrate that GVHD caused a significant decrease in protein levels of
membrane-tethered Muc4 but did not cause any notable change in protein levels of
membrane-tethered Muc1 or Muc16. Interestingly, a significant increase in Muc1 gene
expression was observed in the corneas of GVHD mice, which can possibly be a
compensatory response to partially circumvent the GVHD-mediated damage to the
ocular surface glycocalyx. Besides membrane-tethered mucins, tear film also contains
soluble mucins. Goblet cells are the primary source of large gel forming mucin Muc5AC
which is secreted into the tear film31,32. The results of the present study demonstrate
that GVHD has a detrimental effect on goblet cells because a decrease in the number of
goblet cells was observed in the tissue sections obtained from mice suffering from
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GVHD due to allogeneic transplantation. The histology data also consistently
demonstrated partially empty goblet cells, suggesting the possibility that the surviving
goblet cells in the GVHD mice were releasing Muc5AC in the tear film possibly in an
effort to salvage the ongoing damage to the ocular surface. Our observations are further
supported by the ELISA quantification data showing a significant decrease in the tear
film levels of Muc5AC in GVHD mice. Alterations in ocular surface mucins and
glycocalyx has been previously reported in non-autoimmune dry eye and dry eye due to
Sjogren’s disease16-18,29. To the best of our knowledge, this is the first study to
demonstrate that GVHD causes a damage to the ocular surface glycocalyx and alters
ocular surface mucins.
In this study, we used an allogeneic MHC heterozygous mismatch hematopoietic
transplant mouse model to induce ocular GVHD. Our data demonstrate that this
mouse model develops ocular GVHD-associated dry eye as demonstrated by a
significant decrease in tear film and the corneal keratopathy. Previous studies have
shown the development of ocular GVHD in this mouse model and support the results of
the present study23. Using this mouse model, Hassan et al23 have demonstrated that
GVHD hasa detrimental effect on the lacrimal gland. Studies using MHC matched
allogeneic hematopoietic transplant mouse has also shown lacrimal gland damage in
ocular GVHD33-35. However, our data is the first one to demonstrate that besides
lacrimal gland, GVHD also causes damage to the ocular surface glycocalyx.
Rebamipide, an amino acid analog of 2 (1H)-quinolinone, has long been used for
the treatment of gastric ulcers36,37. The ophthalmic formulation of rebamipide has
recently been launched for the treatment of dry eye in Japan 38. Rebamipide has been
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shown to stimulate gastric mucosal prostaglandin production, increase gastric mucus
synthesis, and scavenge reactive oxygen radicals40-42. Recent studies have shown that
rebamipide increases MUC1, MUC4 and MUC16 synthesis in stratified cultures of
human corneal epithelial cells43,44. In vivo administration of rebamipide has been
demonstrated to have an ameliorative effect in mouse model of Sjogren’s syndrome,
superoxide dismutase knockout mice and rabbit model of dry eye46-47. Given the
beneficial effects of rebamipide on mucous layer and dry eye, we tested the effect of
topical administration of rebamipide in GVHD-associated dry eye in mouse model. Our
data demonstrate that topical rebamipide administration provided significant protection
against GVHD associated dry eye as indicated by the sustenance of tear film and a
notable decrease in corneal keratopathy score. Interestingly, topical administration of
BSS vehicle alone also had some ameliorative effect suggesting that keeping the ocular
surface hydrated can partially rescue GVHD-associated corneal keratopathy.
In summary, our results demonstrate that allogeneic transplantation-associated
ocular GVHD can have a significant detrimental effect on ocular surface glycocalyx and
ocular surface mucins. Further, modulation of ocular surface mucins by rebamipide, a
mucin secretagogue, can partially prevent ocular GVHD-associated decrease in tear
film and reduced the severity of corneal keratopathy.
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Figure 1. Tear film volume in mice before (baseline) and at various time points after
allogeneic bone marrow & spleen cell transplantation.
A significant (* p<0.05 compared to baseline) decrease in tear film volume was
observed at 3 weeks after allogeneic transplantation and it remained significantly low for
the tested duration of 8 weeks.

Figure 2. Representative fluorescein-stained images of mouse corneas before (A) and
at 8 weeks (B) after allogeneic bone marrow & spleen cell transplantation.
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Quantification of fluorescein staining (C) showed significant (* p<0.05 compared to
before transplantation) corneal keratopathy at 8 weeks after allogeneic transplantation

Figure 3. Representative confocal Z stacks images of top (A & B) and orthogonal (D &
E) view of mouse corneas stained for glycocalyx (green) using wheat germ agglutinin.
Nuclei are stained blue. Panel A and B is top view of corneas obtained from control
mice that did not receive any transplantation and mice at 8 weeks after allogeneic bone
marrow & spleen cell transplantation. Quantification of percent-stained area (Panel C)
shows a significant decrease (*p<0.05 compared to control mice that received no
transplantation) in the glycocalyx in mice corneas at 8 weeks after allogeneic
transplantation. Panel D & E is orthogonal view of corneas obtained from control mice
that did not receive any transplantation and mice at 8 weeks after allogeneic
transplantation. Quantification (Panel F) shows a significant decrease (*p<0.05
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compared to control mice that received no transplantation) in the glycocalyx thickness in
mice corneas at 8 weeks after allogeneic transplantation. Area and thickness
quantifications were calculated using 16 different images, each of control mice (n=4)
and mice that received allogeneic transplantation (n=4).

Figure 4. Representative images showing periodic acid Schiff’s-stained goblet cells in
the tissue sections obtained from control mice (no transplant) and mice at 8 weeks after
allogeneic bone marrow & spleen cell transplantation
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Figure 5. ELISA quantification of mucin 1, mucin 4, mucin 16, and mucin 5AC in the
corneal homogenates and tears obtained from control mice (no transplant) and mice at
8 weeks after allogeneic bone marrow and spleen cell transplantation. A decrease in
mucin 4 (* p <0.05) and mucin 5AC (* p <0.05) was observed compared to the levels in
control mice that received no allogeneic transplantation.
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Figure 6. Gene expression quantification of mucin 1, mucin 4, mucin 16, and mucin 19
in the corneal homogenates obtained from control mice (no transplant) and mice at 8
weeks after allogeneic bone marrow and spleen cell transplantation. A significant
increase in mucin1 gene expression (* p <0.05) was observed compared to the levels in
control mice that received no allogeneic transplantation.
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Figure 7. Effect of rebamipide ophthalmic drops on allogeneic bone marrow and spleen
cell transplantation-mediated decrease in tear film volume (A) and corneal keratopathy
score (B). Rebamipide attenuated allogeneic transplantation mediated decrease in tear
film volume, and the results were statistically significant (* p<0.05) at 3 and 4 weeks
after the allogeneic transplantation as compared to mice that also received the
allogeneic transplantation but were either treated with BSS vehicle or did not receive
any eye drops. Rebamipide treatment also significantly decreased the corneal
keratopathy score (* p<0.05 compared to no eye drops-treated mice; t p<0.05
compared to BSS vehicle). Animals that received BSS vehicle alone also showed
significantly (* p<0.05) lower corneal keratopathy score compared to mice that received
no eye drops.
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CHAPTER 3
EFFECT OF OSMOTIC STRESS ON NFAT5 AND PROINFLAMMATORY
CYTOKINES GENE EXPRESSION IN OCULAR SURFACE EPITHELIAL CELLS
Abstract
An increase in tear osmolarity is a cardinal feature of dry eye disease. Osmotic stress
has been shown to cause an increase in the expression of proinflammatory cytokines.
The ocular surface is covered by conjunctival and corneal epithelial cells, which may
show a different biological response to osmotic stress. Therefore, we investigated the
effect of hyperosmolar stress on gene expression of NFAT5, a tonicity-regulated
transcription factor and cytokines IL1, IL6, TNFα, and IFN-γ in human conjunctival and
corneal epithelial cells.
Methods: Telomerase immortalized human corneal and conjunctival epithelial cells
were exposed to hyperosmolar cell culture media (430 mOsm) for 12 and 24 hours. The
mRNA was isolated from these cells and was reverse transcribed to cDNA. The cDNA
was used for the quantification of gene expression by real-time PCR.
Results: Hyperosmotic stress caused a 15.8- and 2.2-fold increase in NFAT5 gene
expression in corneal and conjunctival epithelial cells. Hyperosmotic stress also caused
1.5- and 2-fold increase in the gene expression of IL1 in the human conjunctival and
corneal epithelial cells, respectively. Hyperosmotic stress also caused a 3- 4 fold
increase in IL6 expression in conjunctival cells, whereas the increase in IL6 gene
expression was much more robust in human corneal epithelial cells. Similarly,
hyperosmotic stress caused a 2-3 fold increase in TNFα in human conjunctival cells,
whereas a >10-fold increase in TNFα expression was observed in the human corneal
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epithelial cells. Lastly, a 3-4 fold increase in IFN-γ was observed in corneal epithelial
cells compared to a 1.8 fold increase noted in conjunctival epithelial cells.
Conclusion: Our data demonstrated that human conjunctival and corneal epithelial cells
show a differential response to the hyperosmotic stress-mediated change in the gene
expression of NFAT 5 and proinflammatory cytokines. Human corneal epithelial cells
are more sensitive to hyperosmotic stress.
Introduction
Tear Film and Ocular Surface Society defines dry eye disease is a multifactorial
disorder of the ocular surface characterized by impairment and loss of tear
homeostasis, ocular discomfort or pain, and neurosensory abnormalities1-3. Healthy tear
fluid is iso-osmolar, but dry eye disease can cause an increase in tear osmolarity4-5. An
increase in tear osmolarity has also been observed in the tears of GVHD patients.
NFAT5 is activated by phosphorylation under a hyperosmotic environment and is
amongst the few known tonicity-regulated transcription factors in mammalian cells6.
NFAT5 transcriptionally regulates the expression of target genes responsible for organic
osmolytes' metabolism, including aldose reductase, taurine transporter, betaine/GABA
transporter, and sodium/myo-inositol transporter. Osmotic stress also activates stressrelated kinases, and these kinases are responsible for transcription of the
proinflammatory cytokines, thus forming a link between osmolarity and gene expression
of these cytokines6,7. Therefore, we tested the effect of hyperosmolar stress on the
changes in gene expression of NFAT5, IL-1, IL-6, TNF- α, and IFN-γ in human corneal
and conjunctival epithelial cells8-12.
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Methods
Culture of stratified human corneal and conjunctival epithelial cells
Telomerase-transformed human corneal and conjunctival epithelial cell lines were used
for this study. Human corneal epithelial cells were propagated in keratinocyte growth
medium supplemented with bovine pituitary extract (0.004 ml/ml), human epidermal
growth factor (0.125ng/ml), human insulin (5µg/ml), hydrocortisone (0.33µg/ml),
epinephrine (0.39 µg/ml), transferrin (10 µg/ml) and calcium chloride (0.15 mM)
(PromoCell GmbH, Heidelberg, Germany). To induce stratification, the cells were plated
on a collagen-coated 3.0 µm PTFE transwell membrane inserts (Corning Inc., Corning,
NY, USA), and the media was switched to a supplemented keratinocyte growth medium
containing a higher concentration of CaCl2 (1.15 mM). This media was added both on
the inserts and the bottom well until the cells reached 100% confluence. Once the cells
reached 100% confluence, the media was added to the bottom of the well only, leaving
the membrane inserts containing the cells exposed to air for one week to achieve
stratification into a multilayered epithelium.
The human conjunctival epithelial cells were propagated in keratinocyte serumfree medium supplemented with 25 μg/mL bovine pituitary extract, 0.2 ng/mL epidermal
growth factor, and 0.4 mM CaCl2 (Gibco-Invitrogen Corp., Rockville, MD, USA). Once
the cells reached 50% confluence, the media was switched to a 1:1 mixture of
supplemented keratinocyte serum-free medium and low-calcium DMEM without
HEPES/F12 media (Gibco-Invitrogen Corp., Rockville, MD, USA). When the cells
reached 100% confluence, the media was replaced with DMEM/F12 media
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supplemented with 1mM CaCl2, 10% Calf serum, and 10 ng/mL EGF for about 5 to 7
days to induce stratification.
Osmotic stress treatment
Human corneal and conjunctival epithelial cells were exposed to hyperosmolar
cell culture media (430 mOsm) for 12 hours and 24 hours. The hyperosmolar media
was prepared by adding sodium chloride to the isotonic cell culture media. The control
cells were cultured in the isotonic media (300 mOsm). Each experiment was conducted
in triplicate.
Isolation of mRNA and preparation of cDNA
The total RNA from the control and hyperosmolar exposed corneal and
conjunctival epithelial cells were isolated using a commercially available kit (Qiagen’s
RNeasy Mini Kit, Valencia, CA, USA) as per manufacturer’s instructions. The RNA was
immediately reverse transcribed to cDNA using a commercially available kit
(SuperScript® III First-Stand, Invitrogen, Carlsbad, CA, USA).
Cytokine gene expression quantification
The gene expression of cytokines was quantified using Real-Time PCR. A 20 µl
reaction mixture containing 2 µl of cDNA and 18 µl of SYBR Green Master Mix was run
at a universal cycle (95°C for 10 min, 40 cycles at 95°C for 15 seconds, and 55°C for 60
seconds) using Real-Time thermocycler (Biorad CFX thermal cycler, Bio-Rad
Laboratories, Hercules, California, USA). β-actin was used as the housekeeping gene.
The relative change in gene expression was calculated using the ΔΔCt method.
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Results and Discussion
Exposure of human corneal and conjunctival epithelial cells to hyperosmotic
stress caused an average of 15.8- and 2.2-fold increase in NFAT5 gene expression
(Figure 1). For IL-1, there was a 2-fold increase in the gene expression corneal
epithelial cells noted at 24-hour after exposure to hyper-osmolar media. On the other
hand, a 1.5-fold increase in gene expression of IL-1 was noted at 12-hour after
hyperosmolar media exposure in conjunctival epithelial cells (Figure 2). Next, for IL-6,
there was >150-fold, and 3.5-fold increase in gene expression noted at 24-hour after
hyperosmolar media exposure in corneal and conjunctival epithelial cells, respectively
(Figure 3). For TNF-α, there was an 8-fold increase in the 12-hour treated corneal
epithelial cells, a greater than 10-fold increase in the 24-hour treated corneal epithelial
cells, and a 2-fold increase in gene expression in 24-hour treated conjunctival epithelial
cells (Figure 4). Lastly, a 3-4 fold increase in IFN-γ was observed in corneal epithelial
cells compared to a 1.8 fold increase noted in conjunctival epithelial cells.
Based on this data, it can be deduced that hyperosmolar stress increases the gene
expression of NFAT5 and proinflammatory cytokines in human corneal and conjunctival
epithelial cells, and it can be concluded that human corneal epithelial cells are more
sensitive to hyperosmotic stress.
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Figure 1. Effect of hyperosmolar stress on gene expression of NFAT5 in human corneal
and conjunctival epithelial cells. * p< 0.05 versus cells exposed to iso-osmolar media

Figure 2. Effect of hyperosmolar stress on gene expression of IL-1 in human corneal
and conjunctival epithelial cells* p< 0.05 versus cells exposed to iso-osmolar media
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Figure 3. Effect of hyperosmolar stress on gene expression IL-6 in human corneal and
conjunctival epithelial cells. * p< 0.05 versus cells exposed to iso-osmolar media

Figure 4. Effect of hyperosmolar stress on gene expression of TNF-α in human corneal
and conjunctival epithelial cells. * p< 0.05 versus cells exposed to iso-osmolar media
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Figure 5. Effect of hyperosmolar stress on gene expression of IFN-γ in human corneal
and conjunctival epithelial cells. * p< 0.05 versus cells exposed to iso-osmolar media
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Abstract:
Purpose: Proinflammatory cytokines are elevated in tears of patients with dry eye.
Apical surface of ocular surface epithelial cells is covered with membrane-tethered
mucins (MUC) that, together with galactin-3, form glycocalyx network, which plays a
critical role in ocular health. The present study tested the effect of proinflammatory
cytokines IL-6, TNF-α, and IFN-γ on membrane-tethered mucins gene expression,
glycocalyx, and viability of ocular surface epithelial cells.
Methods: Stratified cultures of human corneal and conjunctival epithelial cells were
exposed to five different concentrations of IL-6, TNF-α, and IFN-γ for 24 hours. The
mRNA was isolated, and reverse-transcribed to cDNA for gene expression
quantification using real time PCR. The glycocalyx was stained using Alexa 488conjugated wheat germ agglutinin lectin and images using confocal microscopy.
Apoptotic and necrotic cell death was quantified using flow cytometry.
Results: IL-6, TNF-α, and IFN-γ treatment resulted in a significant increase in the MUC1
and MUC4 gene expression in stratified human corneal epithelial cells but did not cause
a significant change MUC16 expression. Unlike corneal epithelial cells, these cytokines
caused no significant changes in MUC1, MUC4, and MUC16 expression in stratified
human conjunctival epithelial cells. Further, IL-6, TNF-α, and IFN-γ did not cause a
notable change in glycocalyx or apoptotic cell death in stratified human corneal and
conjunctival epithelial cells, but IL-6 resulted in an increase in necrotic cell death in
stratified human corneal epithelial cells while TNF-α caused a significant increase in
necrotic cell death of stratified human conjunctival epithelial cells.
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Conclusions: Our results have shown that IL-6, TNF-α, and IFN-γ have differential
effects on human corneal and conjunctival epithelial cell mucin gene expression,
resulting in an increase in MUC1 and MUC4 gene expression only in stratified human
corneal epithelial cells. Furthermore, these cytokines did not cause significant changes
in stratified human corneal and conjunctival epithelial cell glycocalyx.
Keywords: Mucins, Glycocalyx, Ocular Surface, Proinflammatory Cytokines
Introduction
The apical surface of human corneal and conjunctival epithelial cells is covered
with a layer of glycocalyx that forms a boundary between these cells and the tear film
[1-3]. Glycocalyx is a network made up of membrane-tethered mucins, their side chains,
and galectin-3 [1-7]. Glycocalyx and mucins are critical for ocular health as they serve
many functions, including repelling pathogens, keeping the ocular surface hydrated,
protecting the cells against mechanical and chemical damage, as well as reducing
friction during blinking [1-7].
Dry eye or keratoconjunctivitis sicca is a common ocular condition with a high
global prevalence. The disease is characterized by loss of tear film homeostasis, tear
hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities [8,9].
While multiple factors contribute to the pathogenesis of dry eye, the immune-mediated
inflammatory response plays a central role in its onset and progression [10-14].
Hyperosmolar stress has been shown to trigger the release of proinflammatory
cytokines IL-1, IL-6, TNF-α from ocular surface epithelial cells [15,16]. Hyperosmolar
stress due to increased tear osmolarity in dry eye disease and the associated release of
cytokines can contribute to the early stage of ocular surface inflammation. Levels of IL-6
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and TNF-α have been reported to be elevated in the tears of patients suffering from dry
eye [17]. These proinflammatory cytokines along with chemokines, are also responsible
for activation, maturation, and migration of antigen-presenting cells in the early stages
of dry eye disease [10-14]. Subsequently, activated antigen-presenting cells recruit T
cells which have been shown to secret IL-17 and IFN-γ [10-14]. T cell-derived cytokines
contribute to the amplification stage of inflammation in dry eye disease [10-14].
The promoter region of genes encoding for mucins have response elements for
signaling pathways activated by proinflammatory cytokines, including IL-6, TNF-α, and
IFN-γ, suggesting that these cytokines can modulate the gene expression of mucins
[18-21]. Additionally, these cytokines have been shown to induce the expression of
enzymes such as heparanase and hyaluronidase that may have a detrimental effect on
the glycocalyx [22,23]. Immunological and conjunctiva impression cytology studies have
shown that the levels of mucins or the degree of their glycosylation is notably altered in
both the cornea as well as conjunctiva of patients suffering from Non Sjogren and
Sjogren syndrome-related dry eye disease [1,2,24]. Therefore, the present study is
designed to investigate the effect of two early-stage (IL-6, TNF-α) and one amplification
stage (IFN-γ) proinflammatory cytokines on membrane-tethered mucins (MUC) MUC1,
MUC4, MUC16, ocular surface glycocalyx, and cell viability of human stratified corneal
and human stratified conjunctival epithelial cells. Since patients suffering from dry eye
have elevated tear levels of these cytokines in the picogram range, the present study
tested the effect of these cytokines on ocular surface mucins and glycocalyx at the
pathologically relevant picogram concentrations.
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Methods
Culture of stratified human corneal and conjunctival epithelial cells
Telomerase-transformed human corneal and conjunctival epithelial cell lines
were used for this study. Human corneal epithelial cells were propagated in keratinocyte
growth medium supplemented with bovine pituitary extract (0.004 ml/ml), human
epidermal growth factor (0.125 ng/ml), human insulin (5 µg/ml), hydrocortisone
(0.33µg/ml), epinephrine (0.39 µg/ml), transferrin (10 µg/ml) and calcium chloride (0.15
mM) (PromoCell GmbH, Heidelberg, Germany). To induce stratification, the cells were
plated on a collagen-coated 3.0 µm PTFE transwell membrane inserts (Corning Inc.,
Corning, NY, USA) and the media was switched to supplemented keratinocyte growth
medium containing a higher concentration of CaCl2 (1.15 mM). This media was added
both on the inserts as well as the bottom well until the cells reached 100% confluence.
Once the cells reached 100% confluence, the media was added to the bottom of the
well only, leaving the membrane inserts containing the cells exposed to air for one week
to achieve stratification into a multilayered epithelium [25].
The human conjunctival epithelial cells were propagated in keratinocyte serumfree medium supplemented with 25 μg/mL bovine pituitary extract, 0.2 ng/mL epidermal
growth factor, and 0.4 mM CaCl2 (Gibco-Invitrogen Corp., Rockville, MD, USA). Once
the cells reached 50% confluence, the media was switched to a 1:1 mixture of
supplemented keratinocyte serum-free medium and low-calcium DMEM without
HEPES/F12 media (Gibco-Invitrogen Corp., Rockville, MD, USA). When the cells
reached 100% confluence, the media was replaced with DMEM/F12 media
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supplemented with 1mM CaCl2, 10% Calf serum, and 10 ng/mL EGF for about 5 to 7
days to induce stratification [26,27].
Cytokines treatment
The cytokines were purchased from PeproTech (Cranbury, NJ, USA). To test the
effects of proinflammatory cytokines on mucin expression, glycocalyx, and epithelial
viability, the stratified cultures of human corneal and conjunctival epithelial cells were
separately exposed to IL-6, TNF-α, and IFN-γ at five different concentrations (30, 60,
125, 250, 500 pg/mL) for 24 hours. Each experiment was conducted in quadruplicates.
Isolation of mRNA and preparation of cDNA
The total RNA from the control and cytokine exposed stratified corneal and
conjunctival epithelial cells was isolated using a commercially available kit (Qiagen’s
RNeasy Mini Kit, Valencia, CA, USA) as per the manufacturer’s instructions. The RNA
was immediately reverse transcribed to cDNA using a commercially available kit
(SuperScript® III First-Stand, Invitrogen, Carlsbad, CA, USA).
Mucins gene expression quantification
The gene expression of MUC1, MUC4, and MUC16 was quantified using RealTime PCR. A 20 µl reaction mixture containing 2 µl of cDNA and 18 µl of SYBR Green
Master Mix was run at a universal cycle (95°C for 10 min, 40 cycles at 95°C for 15
seconds and 55°C for 60 seconds) using Real-Time thermocycler (Biorad CFX thermal
cycler, Bio-Rad Laboratories, Hercules, California, USA). β-actin was used as the
housekeeping gene. The relative change in gene expression was calculated using the
ΔΔ

Ct method.
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Glycocalyx staining
The stratified cultures of control and cytokine-exposed human corneal and
conjunctival epithelial cells were fixed in 4% paraformaldehyde. The cells were blocked
in 5% BSA for 20 minutes. Glycocalyx was stained using 1.5 μg/mL solution of Alexa
488- conjugated wheat germ agglutinin lectin (Thermo Fisher Scientific, Hanover Park,
IL, USA) for 20 minutes. Wheat germ agglutinin lectin binds to the N-acetylglucosamine
and N-acetylneuraminic acid residues present on the ocular surface glycocalyx and has
been used in multiple studies, including human patients to stain corneal glycocalyx
[28,29]. The stained glycocalyx was imaged using a confocal microscope (Nikon Inc.
Mellville, NY). Four images were captured from the randomly selected areas of each
cultured well (total n=16 for each cytokine since the experiment was in quadruplicates).
The quantification of glycocalyx stained area was performed using Image J software in
a blinded manner.
Flow cytometry quantification of apoptotic and necrotic cell death
The stratified cultures of control and cytokine exposed human corneal and
conjunctival epithelial cells were incubated in a solution containing 1:2000 propidium
iodide and 1: 300 FITC-conjugated annexin V (Cayman Chemical, Ann Harbor, MI,
USA). The populations of stained cells were analyzed using BD FACSverse flow
cytometer (BD Sciences, San Jose, CA, USA). The data was analyzed using FlowJo
software.
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Statistics
The data are presented as mean + Standard error of mean. Statistical analysis
was performed using GraphPad Prism software (GraphPad Prism, Version 8, San
Diego, CA, USA). The data were analyzed using One-Way ANOVA, followed by
Dunnett’s post-hoc test. A p value of <0.05 was considered statistically significant.
Results
Effect of IL-6, TNF-α, and IFN-γ on membrane-tethered mucins gene expression in
stratified human corneal and conjunctival epithelial cells
To test the effect of IL-6, TNF-α, and IFN-γ on ocular surface mucins gene
expression, the stratified human corneal and conjunctival epithelial cells were exposed
to five concentrations of these cytokines. Fig. 1 shows the effect of IL-6 on membranetethered mucins in stratified human corneal and conjunctival epithelial cells. IL-6
treatment caused a significant increase in the gene expression of MUC1 and MUC4 in
the human corneal epithelial cells but did not cause a notable change in the gene
expression of MUC16 (Fig. 1A). IL-6 showed an inverted bell-shaped dose-response
curve with a less pronounced effect at 30 pg/ml followed by a dose-dependent
significant (p<0.05 compared to control cells not exposed to IL-6) increase at 60, 125
and 250 pg/ml then a subsequent decrease in effect at 500 pg/ml for both MUC1 and
MUC4 gene expression. In contrast to the corneal epithelial cells, IL-6 did not
significantly change the MUC1, MUC4, and MUC16 gene expression in stratified human
conjunctival epithelial cells (Fig. 1B).
Fig. 2A shows that TNF-α treatment caused significant (p<0.05 compared to
control cells not exposed to TNF-α) increase in the gene expression of MUC1 and
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MUC4 in stratified human corneal epithelial cells but did not cause any notable change
in MUC16. It is worth noting that the various tested concentrations of TNF-α caused a
similar increase in the gene expression of MUC1 and MUC4 suggesting that the effect
of TNF-α may not be dose-dependent but a likely response of all or none pattern. On
the other hand, TNF-α did not cause any notable change in MUC1, MUC4, and MUC16
expression in the stratified human conjunctival epithelial cells (Fig. 2B).
Consistent with the effects observed with IL-6 and TNF-α, IFN-γ exposure also
caused a significant (p<0.05 compared to control cells not exposed to IFN-γ) increase in
the gene expression of MUC1 and MUC4 in the stratified human corneal epithelial cells
but did not cause any change in MUC16 gene expression (Fig. 3A). Just like TNF-α,
various doses of IFN-γ also caused a similar increase in the gene expression of MUC1
and MUC4, suggesting that the effect of IFN-γ are not dose-dependent but follow all or
none response. On the contrary, Fig. 3B shows that IFN-γ did not cause any significant
change in the gene expression of MUC1, MUC4, and MUC 16 in stratified human
conjunctival epithelial cells.
Effect of IL-6, TNF-α and IFN-γ on stratified human corneal and conjunctival
epithelial cell glycocalyx
The integrity of glycocalyx is important for the barrier, lubrication, and hydration
functions of ocular surface epithelial cells [1,2]. Glycocalyx, along with mucins, contains
side-chain structural and chemical components to form a network [1-7]. Proinflammatory
cytokines have been shown to increase enzymes that can digest these components and
damage glycocalyx [22,23]. Therefore, we next tested the effect of these
proinflammatory cytokines on human corneal and conjunctival epithelial cell glycocalyx.
Wheat germ agglutinin lectin binds to the sialic acid residues and has been previously
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used to stain the glycocalyx [28,29]. Fig. 4 shows the top projection of 3-D confocal
images of glycocalyx (stained green with wheat germ agglutinin) in stratified human
corneal epithelial cells. As shown in Fig. 4, treatment of corneal epithelial cells with IL-6,
TNF-α, and IFN-γ (250 pg/ml) did not cause any detrimental effect on corneal epithelial
cells glycocalyx. Digital quantification of randomly captured images revealed an average
stained area of 92 + 6% in control corneal epithelial cells, 93 + 8% in IL-6 treated
corneal epithelial cells, 90 + 10 % in TNF-α treated corneal epithelial cells, and 92 + 9%
in IFN-γ treated stratified human corneal epithelial cells.
Fig. 5 shows the top projection of 3-D confocal images of glycocalyx (stained
green with wheat germ agglutinin) in stratified human conjunctival epithelial cells. As
was seen with the corneal epithelial cells, treatment with IL-6, TNF-α, and IFN-γ (250
pg/ml) did not cause any detrimental effect on conjunctival epithelial cells glycocalyx.
Digital quantification of randomly captured images revealed an average stained area of
80 + 11% in control corneal epithelial cells, 79 + 8% in IL-6 treated corneal epithelial
cells, 81 + 10 % in TNF-α treated corneal epithelial cells, and 77 + 9% in IFN-γ treated
conjunctival epithelial cells.
Effect of IL-6, TNF-α and IFN-γ on stratified human corneal and conjunctival
epithelial cell necrosis and apoptosis
Loss of epithelial cell viability can compromise the ocular surface health and can
perpetuate the inflammation. Therefore, we next tested the effect of IL-6, TNF-α, and
IFN-γ on human corneal and conjunctival epithelial cell necrosis and apoptosis. None of
the cytokines caused any significant increase in apoptotic cell death of human corneal
epithelial cells (Fig. 6A). Interestingly, IL-6 treatment (250 pg/ml) caused a significant
(p<0.05) increase in necrotic cell death (Fig. 6A). Like the effect observed in human
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corneal epithelial cells, none of the tested cytokines caused any increase in apoptotic
cell death of human conjunctival epithelial cells (Fig. 6B). In contrast to human corneal
epithelial cells, TNF-α instead of IL-6 caused a significant (p<0.05) increase in the
necrotic cell death of human conjunctival epithelial cells.
Discussion
Cytokines play an important role in the initiation and perpetuation of dry eye
disease [10-14,30,31]. Exposing ocular surface epithelial cells to hyperosmolar stress
causes the release of proinflammatory cytokines [15,16]. The level of these
proinflammatory cytokines is also significantly increased in the tears of dry eye patients
and the conjunctiva of dry eye patients with Sjogren’s syndrome [17,31,32]. Further, an
inverse correlation has been demonstrated between the levels of these cytokines and
the fluorescein staining and goblet cell density [32].
The apical surface of corneal and conjunctival epithelial cells is covered with
glycocalyx [1-7]. Membrane-tethered mucins are important components of glycocalyx
[1-7]. Multiple studies have shown that proinflammatory cytokines can modulate the
expression of membrane-tethered mucins in oral, nasal, and respiratory mucosal
epithelium [33-36]. The results of this study demonstrate that IL-6, TNF-α, and IFN-γ
increase the expression of MUC1 and MUC4 in the corneal epithelial cells at the
picogram levels. Interestingly, our data demonstrate that these cytokines do not affect
the MUC1 and MUC4 expression in conjunctival epithelial cells. Although both corneal
and conjunctival epithelial cells are reported to express the receptors for these
cytokines [37-39], the differential effect of these cytokines on MUC1 and MUC4 gene
expression in corneal and conjunctival epithelial cells may be due to differences in the
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receptor density, presence of decoy molecules, differential activation of signaling
pathways, or different response of mucin promoters in the two epithelial cell types.
Multiple studies have demonstrated that MUC1 has anti-inflammatory properties due to
the negative regulation of Toll-like receptors [40,41]. Studies have also demonstrated
that MUC1 can act as a microbial scavenger to limit Campylobacter jejuni and
Helicobacter pylori infection in the gastrointestinal tract in a mouse model and limit S.
pneumoniae infection in epithelial cells [42-44]. Therefore, the cytokine-mediated
increase in gene expression of corneal epithelial MUC1 and MUC4 could possibly
represent a physiological response to enhance the ocular surface defense against
microbial stress. Interestingly, none of the three tested cytokines caused any notable
change in the gene expression of MUC16 in both corneal as well as conjunctival
epithelial cells, suggesting that the picogram dose of these cytokines is not sufficient to
modulate MUC16 gene expression.
Cytokines have also been shown to induce the expression of enzymes such as
heparanase and hyaluronidase, which can damage the mucin side chains, thus
compromising the integrity of glycocalyx [22,23]. TNF-α has been shown to induce
endothelial glycocalyx shedding resulting in increased vascular permeability and
aberrant vasodilation [45]. However, the results of the present study demonstrate that
IL-6, TNF-α, and IFN-γ do not have any detrimental effect on corneal and conjunctival
epithelial cell glycocalyx. Lastly, none of the cytokines caused an increase in apoptotic
cell death, but an increase in necrotic cell death was noted with TNF-α in conjunctival
epithelial cells and with IL-6 treatment in corneal epithelial cells.
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In summary, the results of the present study demonstrate that IL-6, TNF-α, and
IFN-γ have differential effects on corneal and conjunctival epithelial cells mucins gene
expression and cause an increase in MUC1 and MUC4 gene expression only in corneal
epithelial cells. Furthermore, these cytokines did not cause any notable change in the
corneal and conjunctival glycocalyx and apoptotic cell death.
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Fig. 1. Effect of IL-6 on MUC1, MUC4, MUC16 gene expression in stratified cultures of
human corneal (A) and conjunctival (B) epithelial cells. The cells were exposed to IL6
for 24 hours.
* p < 0.05 compared to control cells (C) that were not exposed to the cytokine
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Fig. 2. Effect of TNF-α on MUC1, MUC4, MUC16 gene expression in stratified cultures
of human corneal (A) and conjunctival (B) epithelial cells. The cells were exposed to
TNF-α for 24 hours.
* p < 0.05 compared to control cells (C) that were not exposed to the cytokine
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Fig. 3. Effect of IFN-γ on MUC1, MUC4, MUC16 gene expression in stratified cultures
of human corneal (A) and conjunctival (B) epithelial cells. The cells were exposed to
IFN-γ for 24 hours.
* p < 0.05 compared to control cells (C) that were not exposed to the cytokine
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Fig. 4. Representative confocal Z-stack images showing glycocalyx staining in stratified
cultures of human corneal epithelial cells exposed to IL-6, TNF-α, and IFN-γ (250 pg/ml)
for 24 hours. Nuclei are stained blue with DAPI and glycocalyx is stained green with
Alexa-488 conjugated wheat germ agglutinin lectin.
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Fig. 5. Representative confocal Z-stack images showing glycocalyx staining in stratified
cultures of human conjunctival epithelial cells exposed to IL-6, TNF-α, and IFN-γ (250
pg/ml) for 24 hours. Nuclei are stained blue with DAPI and glycocalyx is stained green
with Alexa-488 conjugated wheat germ agglutinin lectin.
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Fig. 6. Flow cytometry quantification of apoptosis and necrosis in stratified human
corneal (A) and conjunctival (B) epithelial cells treatment with IL-6, TNF-α, and IFN-γ
(250 pg/ml) for 24 hours. The cells were stained with annexin V/propidium iodide dual
staining for flow cytometry quantification.
* p < 0.05 as compared with the control cells that were not exposed to any cytokine.
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Abstract
Purpose: The present study was designed to investigate the role of myofibroblast
transdifferentiation and conjunctival renin angiotensin system (RAS) in the pathogenesis
of graft versus host (GVHD)-associated conjunctival fibrosis.
Methods: A mouse model of major histocompatibility-matched allogeneic transplantation
was used to induce GVHD with male B10.D2 mice as donors and BALB/c mice as
recipients. Male BALB/c to female BALB/c syngeneic transplant was used as control.
Chromosome Y staining in the spleen cells obtained from female recipient mice was
used to confirm engraftment. Phenol red thread test and fluorescein staining were used
to quantify tears and corneal keratopathy, respectively. The eye tissue was harvested at
4 and 8 weeks after the transplant for immunostaining of smooth muscle actin, (α-SMA),
a myofibroblast marker, angiotensinogen and angiotensin converting enzyme (ACE).
Conjunctiva was harvested for RNA isolation, cDNA preparation and gene quantification
of α-SMA, angiotensinogen and ACE using real time PCR.
Results: More than 80% spleen cells in recipient mice were chromosome Y positive,
thus conforming to successful engraftment. A significant decrease in tear secretion and
a marked increase in corneal keratopathy score after allogeneic transplant indicated the
onset of ocular GVHD in these mice. A significant increase in α-SMA gene expression
and the presence of a large number of α-SMA positive cells was noted in the bulbar
orbital conjunctiva of mice after allogeneic transplant. Allogenic transplant also caused a
significant increase in the gene expression and protein expression angiotensinogen and
ACE in the subconjunctival eyelid area.
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Conclusion: Results of the present study demonstrate that GVHD-associated
conjunctival fibrosis is accompanied by myofibroblast formation and activation of local
tissue RAS.
Introduction
Allogeneic bone marrow transplantation is a standard treatment for many
hematologic malignancies, hemoglobinopathies, and immunodeficiency diseases.
However, graft versus host disease (GVHD) remains a challenging complication of
allogeneic bone marrow transplantation. It is an immune-mediated condition that causes
damage to many organs, including eyes, with 60%–90% of GVHD patients showing
ocular complications (Kim, 2005; Nassiri et al, 2013). Eyes get affected in both acute
and chronic GVHD, although ocular involvement is more common in patients with
chronic GVHD. Acute GVHD can cause photophobia, hyperemia, conjunctivitis,
lagophthalmos, and corneal ulceration (Franklin et al, 1986; Nassar et al, 2013; Nassiri
et al, 2013; Qiu et al, 2018), whereas chronic GVHD is characterized by severe ocular
surface damage resulting in dry eye, keratinization, epithelial thinning, squamous
metaplasia, corneal ulceration and meibomian gland atrophy (Inamoto et al, 2019;
Nassiri et al, 2013).
Conjunctiva is also significantly affected in chronic GVHD patients with
manifestations such as pseudomembranous conjunctivitis, symblepharon and fornix
shortening (Nassar et al, 2013; Nassiri et al, 2013). Additionally, GVHD patients show a
white scar under their bulbar conjunctiva suggestive of subepithelial conjunctival fibrosis
(Kheirkhah et al, 2018; Kusne et al., 2017). Injury to conjunctival tissue caused by the
chronic inflammatory response due to GVHD can initiate a wound healing response.
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Excessive wound healing response may lead to aberrant extracellular matrix synthesis,
thus resulting in conjunctival fibrosis. Myofibroblasts are contractile metabolically active
cells that synthesis large quantities of extracellular matrix proteins and play a key role in
fibrosis (Hinz et al, 2007; Klingberg et al, 2013; Wynn and Ramalingam, 2012).
Myofibroblasts can form by trans-differentiation of a variety of cells such as resident
fibroblasts, mesenchymal cells, and circulating fibrocytes (Hinz et al, 2007; Klingberg et
al, 2013; Wynn and Ramalingam, 2012). Conjunctiva is a connective tissue containing a
significant number of fibroblasts and presence of donor-origin fibrocytes has also been
demonstrated in the eyes of GVHD patients (Ogawa et al., 2005).
Conjunctival tissue has been shown to express components of local renin
angiotensin system (RAS), including renin, angiotensinogen, angiotensin converting
enzyme (ACE) and AT1 receptors (Holappa et al, 2017; Ramirez et al, 1996; Savaskan
et al, 2004; Sramek et al, 1992; Wagner et al,1996). Like many other organs, role of
angiotensin II, the end effector of RAS pathway, has been implicated in conjunctival
fibrosis (Shi et al, 2015; Ye et al., 2020). Components of RAS are upregulated after
conjunctival injury (Shi et al, 2015). Angiotensin II has been shown to cause
transdifferentiation of tenon’s fibroblasts to myofibroblasts (Ye et al., 2020). Profibrotic
cytokines such as transforming growth factor beta (TGF-β), PDGF, CTGF released by
immune cells in GVHD can serve as initial trigger for fibroblasts transdifferentiation to
myofibroblasts (Dale and Saban, 2015; Ogawa et al., 2018). However, upregulation of
RAS and a cross talk between profibrotic cytokines, especially TGF-β and RAS, can
serve to amplify and perpetuate conjunctival fibrosis. The present study was designed
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to investigate the role of myofibroblast transdifferentiation and conjunctival RAS in the
pathogenesis of GVHD-associated conjunctival fibrosis.
Materials and Methods
Bone marrow transplantation
The animal protocol was approved by the Institutional Animal Care and Use
Committee of Chapman University. All animal experiments were conducted in
accordance with the ARVO statements for eye research. Mouse model of major MHC
match and minor MHC mismatch was used to induce GVHD. Male B10.D2 mice (The
Jackson Laboratories, Bar Harbor, ME, USA) having a homozygous MHC haplotype d/d
were used as donors and female BALB/c mice (The Chares River, Wilmington, MA,
USA) also having a homozygous haplotype d/d were used as recipients. The control
group was syngeneic transplantation, where donors were male BALB/c mice and
recipient were female BALB/c mice. The femurs and spleen cells were harvested from 8
weeks old donor mice, as described in our earlier publication (Shamloo et al., 2019).
Recipient female BALB/c mice were exposed to 700 cGy irradiation using an X-Ray
irradiator (RS 2000 X-ray Biological Irradiator, Rad Source Technologies, Buford, GA,
USA). After 6 hours, the irradiated recipient female BALB/c mice were injected with
2X106 spleen cells and 1X106 bone marrow cells. The mice were fed with diet gel
(ClearH2O, Portland, ME, USA), housed in sterile cages, and received sulfatrim (0.672
mg/mL) in their drinking water for two weeks after the transplant. At four and eight
weeks after the transplantation, animals were euthanized by CO2 administration for the
collection of ocular tissue. The study design included two different groups of mice: 1)
Control group included BALB/c female mice (n=9) that received syngeneic bone marrow
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and spleen cell transplantation from male BALB/c mice 2) Ocular GVHD group included
female BALB/c mice (n =12) that received allogeneic bone marrow and spleen cell
transplantation from male B10/D2 mice.
Monitoring of engraftment
The presence of chromosome Y in the spleen cells of female recipient mice was
used to track engraftment by male donor marrow. A fluorescent paint probe was used to
stain chromosome Y by fluorescent in situ hybridization using a commercially available
kit (Empire genomics, Williamsville, NY). Mice were also monitored for systemic signs of
chronic GVHD, such as loss of body weight and body hair.
Tear quantification
Tear secretion was quantified by phenol red thread (FCI Ophthalmics, Pembroke,
MA, USA) which is pH sensitive and changes from yellow to red upon wetting by tears.
The thread was placed in temporal side of lower eye lid for 1 minute and the length of
color change was measured in millimeters and converted to volume using a standard
plot. A standard curve was plotted by wetting the thread with known volume of artificial
tears and measuring the length of the wetted phenol red thread. Due to the small
amount of tear film volume in the mouse eyes, the phenol red thread test typically
requires longer time to obtain consistent values, accordingly 1-minute duration for
phenol red thread test was used. Tear volume was quantified before the allogeneic and
syngeneic transplantation (baseline) and at week 2, 4, 6 and 8 after the transplantation
(Shamloo et al, 2019).
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Fluorescein staining
Mice were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and
xylazine (5 mg/kg). A 2-μL sterile solution of 0.5% fluorescein was applied to mouse eye
and imaging was performed under cobalt filter with a slit lamp (SL-17, Kowa, USA)
using a digital camera. The captured corneal images were divided into four hypothetical
quadrants for scoring the keratopathy using a previously published method (Shamloo et
al, 2019; Zhang et al, 2014). Each quadrant was scored as follows: no staining = 0;
slightly punctate staining less than 30 spots = 1; punctate staining more than 30 spots,
but not diffuse = 2; diffuse staining but no positive plaque = 3; positive fluorescein
plaque = 4. The scores of each quadrant were added to arrive at a final grade (total
maximum possible score =16).
Tissue harvesting and cryosectioning
Eyes along with the eyelids were harvested from euthanized animals. The tissue
was fixed in 4% paraformaldehyde overnight followed by immersion in 15% and 30%
sucrose, respectively. The tissue was embedded in optimal cutting temperature (OCT)
using 2-methylbutane bath cooled over liquid nitrogen. The sagittal sections were cut
from frozen tissue at 8-μm thickness using cryostat (CM 1860, Leica, Germany) for
performing immunofluorescent staining.
Immunofluorescence staining for α-SMA, angiotensinogen and ACE
Slides containing 8 μm thick sagittal sections of eye and eyelid were rinsed in
phosphate buffer saline (PBS) and blocked with PBS solution containing 2% bovine
serum albumin for 30 min. The tissue sections were then incubated with primary
antibodies for α-SMA (1:1,00 dilution, Invitrogen, Carlsbad, CA), angiotensinogen (1:50
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dilution R&D systems, Minneapolis, MN) and ACE (1:25 dilution R&D systems,
Minneapolis, MN) for 90 minutes. The slides were washed with PBS three times and
incubated with Alexa 488- or Alexa 647-conjugated secondary antibody (1: 500 Dilution,
Abcam, Cambridge, MA) for 60 minutes (Sharma et al., 2009; 2012). The nuclei were
stained with DAPI. The slides were images using confocal microscope (Nikon, Melville,
NY). The number of nuclei showing α-SMA staining and the percent fraction of area
showing angiotensinogen and ACE staining was quantified using Image J.
RNA isolation, cDNA preparation and gene expression quantification
The whole sheet of bulbar conjunctival tissue was removed by using iris scissor
and fine pointed forceps from euthanized animals’ eye at the end of 4 and 8 weeks after
transplantation. The mRNA was extracted using the RNeasy Mini kit (RNeasy kit;
Qiagen Inc., Valencia, CA). The mRNA was immediately reverse transcribed to
complementary DNA (cDNA) using a commercially available kit (Superscript III Firststrand synthesis; Thermo Fisher Scientific). The cDNA was used to quantify α-SMA,
angiotensinogen and ACE gene expressions using real-time PCR. A 20-μL reaction
mixture containing 2 μL of cDNA, 2 μL each of 200 nM of forward primer and reverse
primer (Table 1), and 10 μL of 23 SYBR green super mix was run at a universal cycle
(95 ⁰C for 10 minutes, 40 cycles at 95 ⁰C for 15 seconds, and 550C for 60 seconds) in a
thermocycler (Biorad CFX thermocycler; Bio-Rad Laboratories, Hercules, CA, USA). βactin was used as the housekeeping gene. The relative change in gene expression was
calculated using ΔΔCt method.
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Results
Characterization of GVHD and allogenic transplantation
Mice who received allogeneic transplantation started exhibiting signs of GVHD at
around 4 weeks that included significantly lower body weight (Figure 1A), signs of skin
scleroderma, and loss of body hair (Figure 1B). Interestingly, a sharp decrease in body
weight was observed up to the initial 2 weeks after transplantation in both groups that
received either allogeneic or syngeneic transplantation. This early decrease in body
weight noted in both the groups can be likely attributed to the irradiation stress (Figure 1
A). Both groups regained body weight by week 4. However, the regain of body weight
was significantly lower in mice with allogeneic transplants compared to mice that
received a syngeneic transplant. Furthermore, after this initial recovery, mice with
allogeneic transplant did not show any further gain, and their body weight plateaued,
suggesting the onset of systemic GVHD. On the other hand, mice that received
syngeneic transplantation continued to show an upward trend with a notable increase in
body weight (Figure 1A).
Since the donor mice in our model were male while the recipient mice were
female, we used Y chromosome staining to confirm the successful engraftment of donor
origin marrow cells. Figure 1C shows fluorescent in-situ hybridization staining for
chromosome Y in the spleen cells obtained from recipient female mice at 4 weeks after
allogeneic transplant. Quantification of spleen cells from five different animals showed
an average of 80% spleen cells showing chromosome Y staining, thus confirming the
successful engraftment of recipient mice by cells originating from male donor marrow.
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Clinical signs of ocular GVHD
The mice who received allogeneic transplantation showed signs of ocular GVHD
that included a decrease in tear film and onset of corneal keratopathy. Figure 2 shows
time-dependent changes in tear film volume in mice that received syngeneic and
allogeneic transplantation. Both groups had an average tear volume of 153nl and 137nl
at the baseline prior to transplant. Just like body weight, both groups showed a
decrease in tear film volume at 2 weeks after the transplant, which could be attributed to
irradiation stress-related physiological changes. However, mice that received allogeneic
transplants continued to show a further decline in tear film volume at weeks 6 and 8
after the initial slight regain at week 4. The tear volume in the mice with allogenic
transplant was significantly less compared to mice that received a syngeneic transplant.
Figure 3A shows a representative fluorescein-stained image of mice eyes that received
syngeneic or allogeneic transplantation. The corneas of mice that received allogeneic
transplant showed punctate staining at week 4 and even plaques after week 8.
Quantification of corneal keratopathy showed that both groups had a mean score of 2 at
the baseline (Figure 3B). Mice that received allogenic transplantation showed a
significant increase in the corneal keratopathic score to 6 and 9.3 at 4 weeks and 8
weeks, respectively. The syngeneic mice also showed a slight increase in keratopathy
score to 3.6 at week 8, possibly due to aging (Figure 3B).
Presence of conjunctival myofibroblasts in ocular GVHD
The presence of myofibroblasts is a hallmark feature of fibrosis. Myofibroblasts
express high levels of intracellular bundles of α-SMA. Therefore, to test whether ocular
GVHD causes conjunctival fibrosis due to myofibroblast formation, we used gene
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expression to quantify α-SMA and performed α-SMA immunostaining to detect the
localization of myofibroblasts. A 2.7-fold (p<0.05) and 2.02-fold increase in α-SMA gene
expression was observed in the conjunctival tissue obtained from mice at 4 weeks and
8 weeks after allogeneic transplantation (Figure 4). Furthermore, immunostaining
detected the presence of a large number of α-SMA positive myofibroblasts in bulbar
orbital conjunctiva of mice at 4 and 8 weeks after an allogeneic transplant (Figure 5A).
On the other hand, no myofibroblasts could be detected in the tissue sections obtained
from mice that received a syngeneic transplant (Figure 5A). Quantification of the
number of nuclei showed an average of 1079 α-SMA positive nuclei at 4 weeks and 978
α-SMA positive nuclei at 8 weeks after allogeneic transplantation compared to around
250 α-SMA positive nuclei in mice that received a syngeneic transplant (Figure 5B).
Ocular GVHD and conjunctival RAS activation
To test whether conjunctival fibrosis was accompanied by activation of local
RAS, we quantified gene expression of angiotensinogen and ACE. We also detected
angiotensinogen and ACE localization by performing immunostaining. A statistically
significant 1.4-fold (p<0.05) increase in gene expression of angiotensinogen and a 2fold (p<0.05) increase in gene expression of ACE was observed in the conjunctival
tissue obtained from mice at 4 weeks after allogeneic transplantation. By 8-week time
point, this noted increase in angiotensinogen and ACE returned to the baseline (Figure
6).
Immunostaining detected a large area under the bulbar conjunctiva that was
intensely stained for angiotensinogen (Figure 7A) and ACE (Figure 8A) at 4 weeks after
allogeneic transplant. On the other hand, angiotensinogen and ACE staining was barely
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detectable in the eyelids of mice that received syngeneic transplant. Quantification of
the percentage of the stained area as fraction of total eyelid for angiotensinogen
showed only 4% stained area in mice that received syngeneic transplant but 37%
stained area (p<0.05) and 22% stained area (p<0.05) in mice at 4 weeks and 8 weeks
after the allogeneic transplant, respectively (Figure 7B). Similarly, < 0.4% area showed
ACE staining in mice that received syngeneic transplant compared to 2% (p<0.05) and
1.5% area at 4 weeks and 8 weeks in mice that received allogeneic transplantation
(Figure 8B)
Discussion
Fibrosis is one of the key features of chronic GVHD affecting many organs,
including lungs, skin, and GI tract (Ghimire et al., 2017; Kitko et al, 2012; Min, 2011;
Zeiser and Blazar, 2017). Clinical subepithelial fibrosis appearing as a white scar has
been reported in the eyelids of chronic GVHD patients (Kheirkhah et al, 2018; Kusne et
al., 2017). Studies have also shown a correlation between conjunctival fibrosis and
corneal epitheliopathy, suggesting that conjunctival fibrosis likely contributes to dry eye
and ocular surface damage in GVHD (Kheirkhah et al, 2018; Kusne et al., 2017). The
present study used B10D2 to BALB/c major MHC match and minor MHC mismatch
mouse model to investigate whether this mouse model shows features of conjunctival
fibrosis as characterized by the presence of myofibroblasts. This mouse model exhibits
scleroderma-like features, as is also confirmed in the present study, and the model has
been extensively used to study GVHD-associated fibrosis in various organs (Chu and
Gress, 2008; McCormick et al., 1999; Yaguchi et al., 2013). The results of the present
study demonstrate that this model indeed shows features of conjunctival fibrosis as
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demonstrated by presence of myofibroblasts. Furthermore, the model recapitulates
many other features of ocular GVHD, including dry eye and corneal keratopathy.
Interestingly, conjunctival fibrosis was noted at 4 weeks without any further increase in
severity at 8 weeks, whereas tear film and keratopathy score continued to decline up to
the tested time point of 8 weeks. This trend tentatively suggests that the conjunctival
fibrosis sets in early and may contribute to the ocular surface damage in this model as
is observed in clinical studies.
The repair process during fibrosis typically involves deposition of excessive
extracellular matrix, which results in replacement of normal parenchymal tissue with the
hypertrophic scar tissue. Myofibroblast formation and proliferation is a critical step in
fibrosis (Hinz et al, 2007; Klingberg et al, 2013; Wynn and Ramalingam, 2012).
Myofibroblasts are metabolically active cells, which synthesize and secrete large
quantities of extracellular matrix during fibrosis (Hinz et al, 2007; Klingberg et al, 2013;
Wynn and Ramalingam, 2012). Myofibroblasts also contribute to altered mechanical
properties of the tissues because they express high amounts of contractile bundles of
cytoskeletal protein, α-SMA. The present study demonstrates a large number of α-SMA
positive myofibroblasts in the orbital bulbar conjunctiva, suggesting that GVHDassociated conjunctival fibrosis is accompanied by myofibroblast formation. The noted
increase of α-SMA gene expression at week 4 after transplantation followed by a
decline at week 8, but a comparable number of α-SMA-stained cells suggest an initial
proliferative phase of myofibroblast formation after allogeneic transplantation followed
by stabilization phase. The resolution phase of fibrosis is typically characterized by a
decline in the myofibroblast number due to apoptosis and other mechanisms.

89

Interestingly, results of the current study demonstrate that resolution of GVHDassociated conjunctival fibrosis likely requires a longer duration since a significant
number of myofibroblasts were still present in the conjunctiva of GVHD mice up to the
tested time point of 8 weeks. Furthermore, a shortening of eyelid and fornix was also
consistently observed in the eyes of GVHD mice at 8 weeks. Given the detection of
large populations of myofibroblasts and their localization in bulbar orbital conjunctiva of
GVHD mice, it is highly likely that the tissue contractile changes caused by these
myofibroblasts may be contributing to the noted alteration in the eyelid and fornix
architect of these GVHD mice.
GVHD is an immune condition mediated by a complex interplay between donor
immune cells and host tissue. Immune cells of donor origin have been shown to be
present in the recipient conjunctival tissue (Tatematsu et al., 2012). These immune cells
can release a variety of profibrotic cytokines such as TGF-β, PDGF, CTGF that can
trigger fibroblast activation and their transdifferentiation to myofibroblasts (Mack, 2018
Rockey et al., 2015; Smigiel et al., 2018; Weiskirchen et al., 2019; Wynn, 2008).
Further, these immune cells and activated fibroblasts also secrete profibrotic vasoactive
peptides such as endothelin and angiotensin that can perpetuate a vicious cycle of
excessive wound healing and fibrosis (Mack, 2018; Rockey et al., 2015; Smigiel et al.,
2018; Weiskirchen et al., 2019; Wynn, 2008). Activation of RAS and elevated levels of
its effector molecule ang II have been shown to play a critical role in mediating fibrosis
in liver, skin, lungs, and cardiac tissue (Abdul-Hafez et al., 2018; Ferrario, 2016; Jia et
al., 2018; Munshi et al., 2011; Wang et al., 2015). Ocular tissue has been shown to
express all components of RAS (Holappa et al, 2017; Savaskan et al, 2004; Sramek et
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al, 1992; Ramirez et al, 1996; Wagner et al,1996). Overaction of RAS has been shown
to play a critical role in conjunctival fibrosis after trabeculectomy (Shi et al., 2015; Ye et
al., 2020). Results of the present study demonstrate that GVHD-associated
myofibroblast formation was accompanied by a significant increase in the gene and
protein expression of angiotensinogen and angiotensin converting enzyme in the tissue
around conjunctiva. Angiotensin II, directly or through increased levels of TGF-β, can
promote fibroblast proliferation and myofibroblast differentiation. Therefore, the noted
increase in local angiotensinogen and ACE activity observed in this study is likely to be
an important contributor to the initiation and perpetuation of conjunctival fibrosis and
myofibroblast formation. Overlapping temporal kinetics between the concomitant
increase in angiotensinogen and ACE and an increase in SMA expression, as noted in
the present study, further supports this hypothesis.
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Figure 1: Body weight of mice before (baseline) and at various time points after
syngeneic and allogeneic transplantation (A). A significant (* p < 0.05) decrease in body
weight was observed in mice who received an allogeneic transplant compared to mice
with a syngeneic transplant. Representative photograph (B) showing signs of
sclerodermatous skin lesions and hair loss in mice who received an allogeneic
transplant. Spleen cells of recipient (female) mice showing Y chromosome staining
confirming successful engraftment of donor (male) graft.
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Figure 2: Tear film volume in mice before (baseline) and at various time points after
syngeneic and allogeneic transplantation. A significant (* p < 0.05) decrease in tear film
volume was observed in mice who received an allogeneic transplant compared to mice
with a syngeneic transplant.
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Figure 3: Representative fluorescein-stained images of corneas at 8 weeks after
syngeneic transplant (control) and at 4 weeks, 8 weeks after allogeneic transplant
(GVHD). Quantification of fluorescein staining (B) showed significant (* p < 0.05)
compared with syngeneic and before transplantation) corneal keratopathy at 4 and 8
weeks after allogeneic transplantation.
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Figure 4: Gene expression quantification of α-smooth muscle actin in conjunctival
homogenates obtained from mice at 8 weeks after syngeneic transplant (control) and at
4 weeks, 8 weeks after allogeneic transplant (GVHD). A significant increase in α-smooth
muscle actin gene expression was noted in conjunctival homogenates obtained from
mice (*p<0.05) after allogeneic transplant compared to the tissues obtained from mice
that received syngeneic transplant.
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Figure 5: Representative confocal images (A) showing immunofluorescent staining
(green) for α-smooth muscle actin in the eyelid tissue sections obtained from mice at 8
weeks after syngeneic transplant (control) and at 4 weeks, 8 weeks after an allogeneic
transplant (GVHD). Nuclei are stained blue with DAPI. Graph (B) shows quantification of
α-smooth muscle actin-stained nuclei in images obtained from 5 different slides, each
from n=5 mice. A significant increase (* p<0.05) in α-smooth muscle actin-stained nuclei
was observed in tissues obtained from mice at 4 weeks and 8 weeks after allogeneic
transplant compared to the tissues obtained from mice that received a syngeneic
transplant.
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Figure 6: Gene expression quantification of angiotensinogen and angiotensin
converting enzyme in conjunctival homogenates obtained from mice at 8 weeks after
syngeneic transplant (control) and at 4 weeks, 8 weeks after allogeneic transplant
(GVHD). A significant increase in angiotensinogen and angiotensin converting enzyme
gene expression was noted in conjunctival homogenates obtained from mice (*p<0.05)
after allogeneic transplant compared to the tissues obtained from mice that received a
syngeneic transplant.
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Figure 7: Representative confocal images (A) showing immunofluorescent staining
(green) for angiotensinogen in the eyelid tissue sections obtained from mice at 8 weeks
after syngeneic transplant (control) and at 4 weeks, 8 weeks after an allogeneic
transplant (GVHD). Nuclei are stained blue with DAPI. Graph (B) shows quantification of
angiotensinogen-stained area (calculated as a fraction of total eyelid area) using images
obtained from 5 different slides each from n=5 mice. A significant increase (* p<0.05) in
angiotensinogen-stained area was observed in tissues obtained from mice at 4 weeks
and 8 weeks after allogeneic transplant compared to the tissues obtained from mice that
received a syngeneic transplant.
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Figure 8: Representative confocal images (A) showing immunofluorescent staining
(red) for angiotensin converting enzyme in the eyelid tissue sections obtained from mice
at 8 weeks after syngeneic transplant (control) and at 4 weeks, 8 weeks after allogeneic
transplant (GVHD). Nuclei are stained blue with DAPI. Graph (B) shows quantification of
angiotensinogen-stained area (calculated as a fraction of total eyelid area) using images
obtained from 5 different slides each from n=5 mice. An increase in angiotensin
converting enzyme-stained area was observed in tissues obtained from mice at 4 weeks
(* p<0.05) and 8 weeks after allogeneic transplant compared to the tissues obtained
from mice that received syngeneic transplant.
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Table 1: Sequence of forward and reverse primers used for Real-Time PCR

Reverse Primer

Forward Primer

Angiotensinogen

5’CAA GTT GAT CTT CCA CCC TGT C3’

5’TCC CAC GCT CTC TGG ATT TA3’

ACE

5’TTG CTG CCC TCT ATG GTA ATG3’

5’GAC AGG TTC GTG GAA GAG TAT G3’

SMA

5’GGC AGT AGT CAC GAA GGA ATA G3’

5’CCA TCA TGC GTC TGG ACT T3’

β-Actin

5’CCA AGA AGG AAG GCT GGA AA3’

5’CTC CCT GGA GAA GAG CTA TGA3’

Gene
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CHAPTER 6

Discussion, Conclusion and Future Direction
GVHD is a significant complication after stem cell transplantation that happens
due to abnormal immune response to the healthy host tissue. It can cause damage to
vital organs, including the eye and results in dry eye disease 1-5.
Dry eye is a multifactorial disease of the ocular surface characterized by loss of
tear film homeostasis characterized by tear film instability, hyperosmolarity, ocular
surface inflammation, and neurosensory abnormalities6. Tear film is composed of three
layers. Outer lipid layer which is produced by the meibomian gland, and it covers the
tear surface to prevent tear film evaporation. The middle aqueous layer produced by
lacrimal gland, lubricates the eye surface and provides oxygen and nutrients to the
cornea. Inner mucin layer retains tear to the eye surface, repels microbes and lubricates
the eye surface 7. Hemostasis of these three layers maintains the ocular surface's
health, and damage to any aspect of these components leads to dry eye disease 6,8.
The pathogenesis of GVHD-associated dry eye is incompletely understood.
Previous studies have shown that GVHD causes fibrosis of lacrimal glands, which could
potentially lead to reduced aqueous layer, thus resulting in ocular surface dryness 9,10.
However, the lipid and mucin layer's role have not been studied in GVHD-associated
dry eye disease. Studies in Sjögren and non-Sjögren related dry eye disease
demonstrated a decrease in ocular surface mucins and glycocalyx barrier 10,11. Another
study among contact lens wearers showed that solutions containing purified gastric
mucins could help relief against dry eye 12. However, the effect of GVHD on ocular
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surface mucins is not studied yet; therefore, we decided to investigate ocular surface
mucins' role in GVHD-associated dry eye disease. Our GVHD mouse model
demonstrated clinical signs of dry eye disease, as was evident from the decreased tear
film and the presence of keratopathies. In this work, for the first time, we demonstrate
that GVHD causes damage to the ocular surface glycocalyx and causes alteration of
ocular surface mucins. Our results are in agreement with previous observations of
decreased mucins in Sjögren disease-related dry eye disease13,14. In vivo administration
of rebamipide has been demonstrated to have a beneficial effect on Sjogren’s syndrome
by increasing glycocalyx barrier14. In this study, we tested the effect of rebamipide, a
mucin secretagogue, on the GVHD-associated dry eye mouse model, which provided a
significant protection against GVHD-associated dry eye by the maintaining of tear film
secretion and a notable decrease in corneal keratopathy score. Although in this study,
we investigated the effect of GVHD on specific mucins, but we did not investigate
rebamipide's effect in the alteration of specific ocular surface mucins. Previous studies
on stratified human cultured corneal epithelial cells, which were treated by rebamipide,
have demonstrated an increase of mucin1615. These findings indicated that rebamipide
might repair glycocalyx barrier disruption in dry eye disease as was noted in our data,
through MUC16 protein expression.
Multiple possible mechanism can contribute to the decrease in mucins and
damage to glycocalyx that we noted in our first study. Conjunctiva forms a large part of
ocular surface, contains goblet cells and contributes to both secreted and membranetethered ocular surface mucins. Multiorgan fibrosis is a well-known complication in
patients with chronic GVHD (cGVHD). While skin, liver, and gastrointestinal involvement
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are the most common manifestations of acute GVHD, cGVHD may affect any organ,
including lungs, skin, and eyes 16-18. Scleroderma-like changes and bronchiolitis
obliterans syndrome are two of the most damaging outcomes in these patients, which
were reported in 5 to 15 percent of patients with cGVHD 19. Ocular involvement in
cGVHD is also very common and appears as severe ocular surface damage causing
dry eye, keratinization, epithelial thinning, squamous metaplasia, corneal ulceration and
meibomian gland atrophy 4,5,20. cGVHD has already been shown to cause an
inflammatory destruction of the lacrimal glands with fibrosis, which decreases tear
production, increases tear film osmalarity, and leads to dry eye disease 9,10. Conjunctiva
is also significantly affected in chronic GVHD patients with pseudomembranous
conjunctivitis, symblepharon, and fornix shortening manifestations 5,21. Clinical reports
recently demonstrated that GVHD patients show a white scar under their bulbar
conjunctiva which could be indicative of subepithelial conjunctival fibrosis 22,23. These
subepithelial fibrotic changes in conjunctiva, as a goblet cell host, most possibly can
decrease goblet cell density and ocular surface mucin production, and increase tear
evaporation and result in dry eye disease. Our data for the first time demonstrated in a
mouse model of cGVHD that cGVHD causes conjunctival fibrosis and it is accompanied
by the presence of myofibroblasts in orbital conjunctival tissue and in Tenon’s capsule.
Our data support the clinical reports of white eyelid scarring in GVHD patients that are
indirectly suggestive of subconjunctival fibrosis in human GVHD. Furthermore, our
mouse model of GVHD recapitulates many other features of ocular GVHD
manifestations, including dry eye and corneal keratopathy.
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Conjunctiva has local renin angiotensin system (RAS) including renin,
angiotensinogen, angiotensin-converting enzyme (ACE), and AT1 receptors 24-28. A
recent study show that components of RAS are upregulated after conjunctival injury 29
and angiotensin treatment of conjunctival fibroblasts causes their transdifferentiation to
myofibroblasts 30. Like many other organs, we think that angiotensin II, the end effector
of RAS pathway, could play a role in conjunctival fibrosis. Angiotensin II could also
potentiate the profibrotic effect of cytokines released by immune cells in GVHD
especially TGF-β1 to transdifferentiate the conjunctival fibroblasts to myofibroblasts.
Our data in mouse model of GVHD demonstrates that conjunctival fibrosis and
myofibroblast formation is accompanied an increase in local angiotensinogen and ACE
levels. Our data support the previous studies that angiotensin II type 1 receptor
antagonist attenuate lung, and liver fibrosis in a murine model of chronic graft-versushost disease31.
It is well known that osmotic stress is an important mechanism of ocular surface
damages in dry eye. Studies have demonstrated that NFAT5 is a fundamental regulator
of the osmotic stress in mammalian cells activated by hyperosmolar stress and had a
detrimental effect in the induction of proinflammatory cytokines and stress-induced
apoptosis in human limbal epithelial cells 32,33. GVHD-mediated damage to ocular
mucins, glycocalyx and conjunctival fibrosis with a resultant increase in tear film
evaporation will also potentially increase the tear osmolarity. Many clinical studies have
reported an increase in tear osmolarity in GVHD patients 31-35. Hyperosmolarity has
been shown to increase the release of proinflammatory cytokines from epithelial cells 36.
Our study also demonstrated that corneal and conjunctival epithelial cells exposure to
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hyperosmolar stress causes an increase in the gene expression of NFAT5 and
cytokines IL-1, IL-6, TNF-α and IFN-γ. Next, we hypothesized that these
proinflammatory cytokines can cause potentially cause a decrease in ocular mucins
expression or can cause damage to glycocalyx as was noted in our fits study. But our
data showed that these cytokines do not cause a decrease in ocular surface mucins but
rather increase their levels or do not cause any damage to glycocalyx. A handful of
studies have shown that proinflammatory cytokines can upregulate mucin gene
expression in chronic inflammatory lung disease and intestinal cancer37-39. Studies have
also reported that MUC1 can act as a microbial scavenger to inhibit bacterial infection in
the gastrointestinal tract in a mouse model and in epithelial cells40-42. Therefore, the
cytokine-mediated increase in gene expression of corneal epithelial MUC1 and MUC4 in
our study could be a response to enhance the ocular surface defense against microbial
stress that can increase cytokine levels. However, there has not been a study about the
role of cytokine mediated changes in mucin expression in the ocular surface epithelium
and our is the first study.
In summary, we investigated the effect of GVHD on tear film volume, corneal
keratopathy, ocular surface glycocalyx, goblet cells, ocular surface mucins, and fibrosis
of conjunctiva. We further studied whether hyperosmolar stress can modulate the
release of pro-inflammatory cytokines from the ocular surface epithelial cells and if
these pro-inflammatory cytokines can cause any detrimental changes to ocular surface
glycocalyx and mucins. In Chapter 2, our data demonstrated that ocular GVHDassociated dry eye is characterized by a significant decrease in tear film volume and the
onset of corneal keratopathy. Ocular GVHD caused a significant decrease in the area
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and thickness of corneal glycocalyx. A significant decrease in the goblet cells, mucin 4,
and mucin 5AC levels were also observed. Topical treatment with rebamipide, a mucin
secretagogue, partially attenuated ocular GVHD-mediated decrease in tear film volume
and significantly reduced corneal keratopathy severity. In summary, our data
demonstrated that ocular GVHD has a detrimental impact on ocular surface glycocalyx,
and mucins and augmentation of ocular surface mucins is a viable pharmacological
approach to partially prevent ocular GVHD-associated decrease in the tear film and the
severity of corneal keratopathy.
An Increase in tear osmolarity is a cardinal feature of dry eye disease. Osmotic
stress activates stress-related kinases, and these kinases are responsible for increased
transcription of the proinflammatory cytokines. In Chapter 3, we tested the effect of
hyperosmolar stress on the changes in gene expression of NFAT5, a tonicity-regulated
transcription factor and pro-inflammatory cytokines IL-1, IL-6, TNF- α, and IFN-γ using
telomerase-immortalized human corneal and conjunctival epithelial cells. Our data
demonstrated that hyperosmolar stress causes a remarkable increase in NFAT5 and
proinflammatory cytokine gene expression in ocular surface epithelial cells. Human
conjunctival and corneal epithelial cells showed a differential response to the
hyperosmotic stress-mediated change in NFAT 5 and proinflammatory cytokines' gene
expression, with human corneal epithelial cells being more sensitive to the
hyperosmotic stress. The release of proinflammatory cytokines orchestrates the
initiation and perpetuation of ocular surface inflammation. Cytokines IL-1, IL-6, TNF-α,
and IFN-γ have been shown to participate in the early-stage and amplification-stage of
dry eye disease. The levels of IL-6, TNF-α, and IFN-γ are known to be elevated in
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patients suffering from dry eye disease. In Chapter 4, we tested the effect of picogram
concentration of proinflammatory cytokines IL-6, TNF-α, and IFN-γ on the gene
expression of membrane-tethered mucins MUC1, MUC4, MUC16, ocular surface
glycocalyx, and viability of stratified cultures of telomerase-immortalized human corneal
and conjunctival epithelial cells. Our data demonstrated that treatment with IL-6, TNF-α,
and IFN-γ resulted in a significant increase in the gene expression of MUC1 and MUC4
in stratified human corneal epithelial cells but did not cause a significant change in the
gene expression of MUC16. Unlike corneal epithelial cells, these cytokines caused no
significant changes in the expression of the MUC1, MUC4, and MUC16 genes in the
stratified human conjunctival epithelial cells. Further, IL-6, TNF-α, and IFN-γ exposure
did not cause any notable change in the stained area of glycocalyx in the stratified
human corneal and conjunctival epithelial cells. None of the tested cytokines caused
any significant increase in apoptotic cell death in stratified human corneal and
conjunctival epithelial cells. However, treatment with IL-6 resulted in an increase in
necrotic cell death in stratified human corneal epithelial cells. In contrast, TNF- α caused
a significant increase in necrotic cell death of stratified human conjunctival epithelial
cells.
Finally, In Chapter 5, we investigated the role of myofibroblast transdifferentiation
and conjunctival renin-angiotensin system (RAS) in graft versus host (GVHD)
pathogenesis-associated conjunctival fibrosis. Our results demonstrated that ocular
GVHD causes a significant increase in α-SMA gene expression and formation of
myofibroblasts as demonstrated by the presence of α-SMA positive cells in the bulbar
orbital conjunctiva of mice after allogeneic transplant. Ocular GVHD-associated fibrosis
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also accompanies by a concomitant increase in the gene expression and protein
expression of angiotensinogen and ACE in the subconjunctival eyelid area.
Future Directions
Future studies are needed to understand the mechanism of GVHD-mediated damage to
ocular surface mucins and glycocalyx besides conjunctival fibrosis as shown in our
study. Infiltration of ocular surface by donor T cells and T cell-mediated direct damage
to corneal and conjunctival epithelial cells could be one such potential mechanism. The
role of other immune cells including antigen presenting cells, and T regulatory cells and
their interaction with ocular surface epithelial cells also needs to be investigated. Lastly,
these immune cells especially macrophages can cause release of profibrotic cytokines
such TGF-β and PDGF. The profibrotic cytokines can cause activation of other
profibrotic pathways such as renin angiotensin system and transdifferentiation of
fibroblasts to myofibroblasts resulting in ocular fibrosis as was observed in the present
study. Polarization of macrophages from classically activated proinflammatory type to
alternatively activated profibrotic healing type could be a transition in ocular GVHD from
inflammatory to fibrotic phase. Future studies need to address whether GVHD causes
donor macrophage infiltration into host cornea and conjunctiva and whether these
macrophages undergo polarization from M1 proinflammatory type into profibrotic M2
phenotype.
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